Table I-17 <u>US PREVALENCE COUNTS, INVASIVE CANCERS ONLY, JANUARY 1, 2003</u> <u>USING DIFFERENT TUMOR INCLUSION CRITERIA</u>

5-Year Limited Duration

28-year Limited Duration

Site/Sex	1st	lst Per Site	lst Per Site	lst	1st Per Site
	Invasive	in Previous	in Previous	Invasive	in Previous
	Tumor Ever ^c	28 Years ^d	5 Years ^e	Tumor Ever ^c	28 Years ^d
All Sites	3,962,252	4,035,862	4,346,625	9,822,273	9,999,566
Male	2,012,274	2,038,895	2,188,678	4,554,140	4,605,294
Female	1,949,978	1,996,967	2,157,947	5,268,133	5,394,272
Oral Cavity & Pharynx	83,955	95,507	98,496	215,563	235,425
Male	55,821	62,933	64,786	138,069	149,462
Female	28,134	32,574	33,710	77,494	85,963
Esophagus	16,590	19,648	19,648	23,825	27,849
Male	12,747	14,965	14,965	17,985	20,779
Female	3,843	4,683	4,683	5,840	7,070
Stomach	29,257	34,386	34,531	57,098	64,641
Male	17,694	20,964	21,014	32,717	37,242
Female	11,563	13,422	13,517	24,381	27,399
Colon & Rectum	416,089	476,844	484,622	1,012,722	1,122,054
Male	207,662	239,032	242,507	494,463	544,591
Female	208,427	237,812	242,115	518,259	577,463
Liver & Intrahep	12,879	14,747	14,747	16,970	19,172
Male	8,577	9,821	9,821	10,783	12,211
Female	4,302	4,926	4,926	6,187	6,961
Pancreas	20,647	24,183	24,183	27,201	31,313
Male	10,136	11,859	11,859	13,101	15,030
Female	10,511	12,324	12,324	14,100	16,283
Larynx	33,012	37,952	38,189	91,949	100,525
Male	26,366	30,377	30,556	73,689	80,335
Female	6,646	7,575	7,633	18,260	20,190
Lung & Bronchus	204,290	249,735	253,884	340,934	404,089
Male	99,565	122,836	124,721	165,339	195,671
Female	104,725	126,899	129,163	175,595	208,418
Melanoma of the Skin	210,287	231,918	238,857	612,953	652,573
Male	111,633	124,847	129,353	303,073	325,161
Female	98,654	107,071	109,504	309,880	327,412
Breast Female	822,609	880,184	918,327	2,236,730	2,370,054
Cervix Female	43,374	45,413	45,468	183,935	189,267
Corpus & Uterus Female	144,051	161,434	161,482	493,698	532,684
Ovary ^f Female	54,837	62,770	62,781	145,849	162,935

US 2003 cancer prevalence counts are based on 2003 cancer prevalence proportions from the SEER 9 registries and 1/1/2003 US population estimates based on the average of 2002 and 2003 population estimates from the US Bureau of the Census.

(b) Prevalence estimates are ambiguous for those with multiple cancers, unless the tumor inclusion criteria are understood. Depending on the application, different inclusion criteria may be appropriate. This table provides three different methods of tumor inclusion: (c) First invasive tumor ever; (d) First invasive tumor for each cancer site diagnosed during the previous 28 years (1975-2002); (e) First invasive tumor for each cancer site diagnosed during the previous 5 years (1998-2002).

For definitions (d) and (e) all sites is treated as a separate cancer "site".

Consider a woman who had three invasive cancers: Melanoma in 1981; Breast cancer in 1998; Melanoma in 1999.

In method (c) the melanoma is the woman's first cancer, and is counted for the melanoma and all sites 28-year limited duration prevalence. For 5-year limited duration prevalence, the woman is not counted at all since her first cancer occurred more than 5 years prior to 1/1/2003.

In method (d) the 1981 melanoma is counted for the melanoma and all sites 28-year limited duration prevalence. The 1998 breast cancer is counted for the breast 5-year and 28-year limited duration prevalence.

In method (e) the 1998 breast cancer is counted for the breast cancer and all sites 5-year limited duration prevalence. The 1999 melanoma is counted for 5-year limited duration prevalence for melanoma.

Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

Table I-17 - continued <u>US PREVALENCE COUNTS, INVASIVE CANCERS ONLY, JANUARY 1, 2003^a</u> <u>USING DIFFERENT TUMOR INCLUSION CRITERIA^b</u>

5-Year Limited Duration

28-year Limited Duration

Site/Sex	lst Invasive Tumor Ever ^c	lst Per Site in Previous 28 Years ^d	lst Per Site in Previous 5 Years ^e	lst Invasive Tumor Ever ^c	1st Per Site in Previous 28 Years ^d
Prostate					
Male	925,708	996,736	996,805	1,932,939	2,062,326
Testis Male	38,559	39,095	39,651	151,951	153,792
Urinary Bladder	184,975	224,084	226,601	480,880	548,618
Male Female	138,238 46,737	167,628 56,456	169,644 56,957	356,081 124,799	405,065 143,553
remaie	40,737	50,450	30,937	124,799	143,553
Kidney & Renal Pelvis	94,596	113,883	114,668	218,509	250,873
Male Female	56,984 37,612	69,698 44,185	70,246 44,422	129,547 88,962	149,743 101,130
	,	,			,
Brain & Nervous System Male	37,131 19,885	38,985 20,784	39,154 20,884	96,508 51,982	99,298 53,322
Female	17,246	18,201	18,270	44,526	45,976
Thyroid	96,001	103,049	103,251	300,771	315,293
Male	22,362	24,688	24,716	68,236	72,272
Female	73,639	78,361	78,535	232,535	243,021
Hodgkin Lymphoma	33,724	35,148	35,183	131,045	133,819
Male	17,816	18,650	18,661	68,125	69,654
Female	15,908	16,498	16,522	62,920	64,165
Non-Hodgkin Lymphoma	159,781	181,551	182,318	350,868	385,654
Male Female	83,817 75,964	95,629 85,922	96,015 86,303	182,423 168,445	199,759 185,895
Myeloma Male	35,577 19,965	41,051 23,210	41,074 23,233	51,578 28,677	58,336 32,603
Female	15,612	17,841	17,841	22,901	25,733
Leukemia	02 012	92,941	02.000	100 620	200 020
Male	82,812 48,279	54,323	93,009 54,357	192,632 109,292	208,020 118,067
Female	34,533	38,618	38,652	83,340	89,953
Acute Lymphocytic Leuk	13,967	14,109	14,109	47,535	47,775
Male	7,952	8,004	8,004	26,215	26,299
Female	6,015	6,105	6,105	21,320	21,476
Childhood (0-19)	57,723	57,832	58,156	227,872	228,339
Male Female	30,378 27,345	30,418 27,414	30,580 27,576	117,016 110,856	117,217 111,122
Kaposi Sarcoma Male	6,714 6,074	7,243 6,548	7,267 6,572	20,047 18,586	20,990 19,429
Male Female	640	695	6,572	1,461	1,561
Mogotholioma	2 902	2 206	2 206	1 100	1 070
Mesothelioma Male	2,802 1,903	3,396 2,363	3,396 2,363	4,182 2,438	4,870 2,958
Female	899	1,033	1,033	1,744	1,912

US 2003 cancer prevalence counts are based on 2003 cancer prevalence proportions from the SEER 9 registries and 1/1/2003 US population estimates based on the average of 2002 and 2003 population estimates from the US Bureau of the Census.

bcde

Consider a woman who had three invasive cancers: Melanoma in 1981; Breast cancer in 1998; Melanoma in 1999.

In method (c) the melanoma is the woman's first cancer, and is counted for the melanoma and all sites 28-year limited duration prevalence. For 5-year limited duration prevalence, the woman is not counted at all since her first cancer occurred more than 5 years prior to 1/1/2003.

In method (d) the 1981 melanoma is counted for the melanoma and all sites 28-year limited duration prevalence. The 1998 breast cancer is counted for the breast 5-year and 28-year limited duration prevalence.

In method (e) the 1998 breast cancer is counted for the breast cancer and all sites 5-year limited duration prevalence. The 1999 melanoma is counted for 5-year limited duration prevalence for melanoma.

⁽b) Prevalence estimates are ambiguous for those with multiple cancers, unless the tumor inclusion criteria are understood. Depending on the application, different inclusion criteria may be appropriate. This table provides three different methods of tumor inclusion: (c) First invasive tumor ever; (d) First invasive tumor for each cancer site diagnosed during the previous 28 years (1975-2002); (e) First invasive tumor for each cancer site diagnosed during the previous 5 years (1998-2002). For definitions (d) and (e) all sites is treated as a separate cancer "site".

Table I-18

<u>US COMPLETE PREVALENCE COUNTS, INVASIVE CANCERS ONLY, JANUARY 1, 2003^a</u>

<u>BY AGE AT PREVALENCE</u>

No. No.		Age Specific										
Males Male	Age at Prevalence	All Ages ^c	0-9	10-19			40-49	50-59	60-69	70+		
Males Male												
Males 4,692,382 16,647 37,774 65,287 145,909 311,209 617,614 1,03,685 2,434,257 Females 5,803,603 14,602 31,271 70,291 210,983 311,209 617,614 1,036,695 2,434,257 Coral Cavity & Pharym Remailes 150,051 57 455 1,232 3,429 14,435 31,522 36,748 62,173 Females 18,104 0 0 46 184 1,124 3,858 5,475 7,418 Females 18,104 0 0 46 184 1,124 3,858 5,475 7,418 Females 5,961 0 12 94 500 2,064 4,793 8,224 18,587 Females 34,299 5 12 94 500 2,064 4,793 8,224 18,587 Females 35,4789 11 36 823 4,550 18,576 50,643 93,617 381,313												
Pemales 1,803,603 14,602 31,271 70,291 210,983 572,039 1,012,808 1,208,754 2,682,855												
Carl Cavity & Pharynx												
Males 150,051 57 455 1,232 3,429 14,435 31,522 36,748 62,173 Females 85,582 97 431 1,580 3,259 8,175 14,170 18,342 39,528 Esophagus Males 18,104 0 0 46 184 1,124 3,858 5,475 7,418 Females 5,961 0 12 94 520 2,064 4,793 8,224 18,587 Stomach Males 34,299 5 12 94 520 2,064 4,793 8,224 18,587 Females 25,554 11 35 86 493 1,711 2,949 4,431 15,618 Colon & Rectum Males 514,789 11 46 768 4,757 19,996 59,515 114,125 315,571 Females 10,850 264 363 253 245 1,279 3,041 2,380	Females	5,803,603	14,602	31,271	70,291	210,983	572,039	1,012,808	1,208,754	2,682,855		
Females	Oral Cavity & Pharynx											
Resorbing	Males	150,051	57	455	1,232	3,429	14,435	31,522	36,748	62,173		
Males Females 18,104 5,961 0 0 46 184 264 1,124 264 3,858 3,475 3,475 7,418 3,458 7,418 3,451 1,518 3,451 1,518 3,451 1,518 3,451 1,518 3,451 1,518 3,451 1,518 3,451 1,518 3,451 1,518 3,451 1,518 3,451 1,518 3,451 1,518 3,451 1,518 3,451 1,518 3,451 1,518 3,451 1,518 3	Females	85,582	97	431	1,580	3,259	8,175	14,170	18,342	39,528		
Males Females 18,104 5,961 0 0 46 184 264 1,124 264 3,858 3,475 3,475 7,418 3,458 7,418 3,451 1,518 3,451 1,518 3,451 1,518 3,451 1,518 3,451 1,518 3,451 1,518 3,451 1,518 3,451 1,518 3,451 1,518 3,451 1,518 3,451 1,518 3,451 1,518 3,451 1,518 3,451 1,518 3,451 1,518 3	Esophagus											
Stomach Males 34,299 5 12 94 520 2,064 4,793 8,224 18,587 Females 25,554 11 35 86 493 1,731 2,949 4,431 15,818 Colon & Rectum Males 514,789 11 46 768 4,757 19,996 59,515 114,125 315,571 Females 553,409 11 58 823 4,550 18,576 50,643 93,617 385,131 Liver & Intrahep Males 10,850 264 363 253 245 1,279 3,041 2,380 3,026 Females 64,95 337 304 242 342 684 993 1,368 2,224 Pancreas Males 13,302 0 47 34 361 1,237 2,846 3,532 5,245 Females 14,386 0 64 114 291 1,325 2,347 3,407 6,839 Larynx Males 78,071 0 12 33 262 2,949 11,097 21,300 42,418 Females 19,242 0 0 55 189 1,322 2,564 5,483 9,630 Lung & Bronchus Males 78,071 0 12 33 262 2,949 11,097 21,300 42,418 Females 19,242 0 0 55 189 1,322 2,564 5,483 9,630 Lung & Bronchus Males 173,431 34 64 264 1,096 6,579 23,655 50,459 91,279 Females 181,558 0 22 388 1,445 7,503 25,227 49,299 97,674 Melanoma of the Skin Males 320,178 55 537 4,417 16,136 46,262 72,977 70,992 108,800		18,104	0	0	46	184	1,124	3,858	5,475	7,418		
Males Females 34,299 (25,554) 5 12 (25,554) 94 (25,554) 50 (20,04) 4,793 (20,44) 8,224 (20,48) 18,587 (25,58) 18,587 (25,58) 18,587 (25,58) 18,587 (25,58) 18,588 (25,58) (Females	5,961	0	12	11	44	264	807	1,363	3,459		
Females 25,554	Stomach											
Colon & Rectum Males 514,789 11 46 768 4,757 19,996 59,515 114,125 315,571 Females 553,409 11 58 823 4,550 18,576 50,643 93,617 385,131 Liver & Intrahep Males 10,850 264 363 253 245 1,279 3,041 2,380 3,026 Females 6,495 337 304 242 342 684 993 1,368 2,224 Pancreas Males 13,302 0 47 34 361 1,237 2,846 3,532 5,245 Females 14,386 0 64 114 291 1,325 2,347 3,407 6,839 Larynx Males 78,071 0 12 33 262 2,949 11,097 21,300 42,418 Females 19,242 0 58 189 1,322 2,564 5,483 9,630 Lung & Bronchus Males 173,431 34 64 264 1,096 6,579 23,655 50,459 91,279 Females 181,558 0 22 388 1,445 7,503 25,227 49,299 97,674	Males	34,299	5	12	94	520	2,064	4,793	8,224	18,587		
Males Females 514,789 553,409 11 46 58 823 4,757 4,500 19,996 59,515 50,643 59,515 93,617 385,131 Liver & Intrahep Males 6,495 10,850 264 363 253 245 1,279 3,041 2,380 3,026 Females 10,850 37 304 242 342 684 993 1,368 2,224 Pancreas Males 13,302 0 47 34 361 1,237 2,846 3,532 5,245 Females 114,386 0 64 114 291 1,325 2,347 3,407 6,839 Larynx Males 78,071 0 12 233 262 2,949 11,097 21,300 42,418 Females 19,242 0 0 0 55 189 1,322 2,564 5,483 9,630 Lung & Bronchus Males 13,431 34 64 264 1,096 6,579 23,655 50,459 91,279 Females 173,431 34 64 264 1,096 6,579 23,655 50,459 97,674 Melanoma of the Skin Males 320,178 55 537 4,417 16,136 46,262 72,977 70,992 108,800	Females	25,554	11	35	86	493	1,731	2,949	4,431	15,818		
Females 553,409 11 58 823 4,550 18,576 50,643 93,617 385,131	Colon & Rectum											
Liver & Intrahep Males 10,850 264 363 253 245 1,279 3,041 2,380 3,026 7emales 6,495 337 304 242 342 684 993 1,368 2,224 Pancreas Males 13,302 0 47 34 361 1,237 2,846 3,532 5,245 7emales 14,386 0 64 114 291 1,325 2,347 3,407 6,839 Larynx Males 78,071 0 12 33 262 2,949 11,097 21,300 42,418 7emales 19,242 0 0 55 189 1,322 2,564 5,483 9,630 Lung & Bronchus Males 173,431 34 64 264 1,096 6,579 23,655 50,459 91,279 7emales 181,558 0 22 388 1,445 7,503 25,227 49,299 97,674	Males	514,789	11	46	768	4,757	19,996	59,515	114,125	315,571		
Males 10,850 264 363 253 245 1,279 3,041 2,380 3,026 Females 6,495 337 304 242 342 684 993 1,368 2,224 Pancreas Males 13,302 0 47 34 361 1,237 2,846 3,532 5,245 5245	Females	553,409	11	58	823	4,550	18,576	50,643	93,617	385,131		
Females 6,495 337 304 242 342 684 993 1,368 2,224 Pancreas Males 13,302 0 47 34 361 1,237 2,846 3,532 5,245 Females 14,386 0 64 114 291 1,325 2,347 3,407 6,839 Larynx Males 78,071 0 12 33 262 2,949 11,097 21,300 42,418 Females 19,242 0 0 55 189 1,322 2,564 5,483 9,630 Lung & Bronchus Males 173,431 34 64 264 1,096 6,579 23,655 50,459 91,279 Females 181,558 0 22 388 1,445 7,503 25,227 49,299 97,674 Melanoma of the Skin Males 320,178 55 537 4,417 16,136 46,262	Liver & Intrahep											
Pancreas Males 13,302 0 47 34 361 1,237 2,846 3,532 5,245 Females 14,386 0 64 114 291 1,325 2,347 3,407 6,839 Larynx Males 78,071 0 12 33 262 2,949 11,097 21,300 42,418 Females 19,242 0 0 55 189 1,322 2,564 5,483 9,630 Lung & Bronchus Males 173,431 34 64 264 1,096 6,579 23,655 50,459 91,279 Females 181,558 0 22 388 1,445 7,503 25,227 49,299 97,674 Melanoma of the Skin Males 320,178 55 537 4,417 16,136 46,262 72,977 70,992 108,800	Males	10,850	264	363	253	245	1,279	3,041	2,380	3,026		
Males 13,302 0 47 34 361 1,237 2,846 3,532 5,245 Females 14,386 0 64 114 291 1,325 2,347 3,407 6,839 Larynx Males 78,071 0 12 33 262 2,949 11,097 21,300 42,418 Females 19,242 0 0 55 189 1,322 2,564 5,483 9,630 Lung & Bronchus Males 173,431 34 64 264 1,096 6,579 23,655 50,459 91,279 Females 181,558 0 22 388 1,445 7,503 25,227 49,299 97,674 Melanoma of the Skin Males 320,178 55 537 4,417 16,136 46,262 72,977 70,992 108,800	Females	6,495	337	304	242	342	684	993	1,368	2,224		
Females 14,386 0 64 114 291 1,325 2,347 3,407 6,839 Larynx Males 78,071 0 12 33 262 2,949 11,097 21,300 42,418 Females 19,242 0 0 55 189 1,322 2,564 5,483 9,630 Lung & Bronchus Males 173,431 34 64 264 1,096 6,579 23,655 50,459 91,279 Females 181,558 0 22 388 1,445 7,503 25,227 49,299 97,674 Melanoma of the Skin Males 320,178 55 537 4,417 16,136 46,262 72,977 70,992 108,800	Pancreas											
Larynx Males 78,071 0 12 33 262 2,949 11,097 21,300 42,418 Females 19,242 0 0 55 189 1,322 2,564 5,483 9,630 Lung & Bronchus Males 173,431 34 64 264 1,096 6,579 23,655 50,459 91,279 Females 181,558 0 22 388 1,445 7,503 25,227 49,299 97,674 Melanoma of the Skin Males 320,178 55 537 4,417 16,136 46,262 72,977 70,992 108,800	Males	13,302	0	47	34	361	1,237	2,846	3,532	5,245		
Males 78,071 0 12 33 262 2,949 11,097 21,300 42,418 Females 19,242 0 0 0 55 189 1,322 2,564 5,483 9,630 Lung & Bronchus	Females	14,386	0	64	114	291	1,325	2,347	3,407	6,839		
Females 19,242 0 0 55 189 1,322 2,564 5,483 9,630 Lung & Bronchus Males 173,431 34 64 264 1,096 6,579 23,655 50,459 91,279 Females 181,558 0 22 388 1,445 7,503 25,227 49,299 97,674 Melanoma of the Skin Males 320,178 55 537 4,417 16,136 46,262 72,977 70,992 108,800	Larynx											
Lung & Bronchus Males 173,431 34 64 264 1,096 6,579 23,655 50,459 91,279 Females 181,558 0 22 388 1,445 7,503 25,227 49,299 97,674 Melanoma of the Skin Males 320,178 55 537 4,417 16,136 46,262 72,977 70,992 108,800	Males	78,071	0	12	33	262	2,949	11,097	21,300	42,418		
Males 173,431 34 64 264 1,096 6,579 23,655 50,459 91,279 Females 181,558 0 22 388 1,445 7,503 25,227 49,299 97,674 Melanoma of the Skin Males 320,178 55 537 4,417 16,136 46,262 72,977 70,992 108,800	Females	19,242	0	0	55	189	1,322	2,564	5,483	9,630		
Females 181,558 0 22 388 1,445 7,503 25,227 49,299 97,674 Melanoma of the Skin Males 320,178 55 537 4,417 16,136 46,262 72,977 70,992 108,800	Lung & Bronchus											
Melanoma of the Skin Males 320,178 55 537 4,417 16,136 46,262 72,977 70,992 108,800	Males	173,431	34	64	264	1,096	6,579	23,655	50,459	91,279		
Males 320,178 55 537 4,417 16,136 46,262 72,977 70,992 108,800	Females	181,558	0	22	388	1,445	7,503	25,227	49,299	97,674		
	Melanoma of the Skin											
Females 342,255 68 886 8,787 30,219 65,632 79,188 60,803 96,672	Males	320,178	55	537	4,417	16,136	46,262	72,977	70,992	108,800		
	Females	342,255	68	886	8,787	30,219	65,632	79,188	60,803	96,672		

US 2003 cancer prevalence counts are based on 2003 cancer prevalence proportions from the SEER 9 registries (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta) and 1/1/2003 US population estimates based on the average of 2002 and 2003 population estimates from the US Bureau of the Census. Prevalence was calculated using the First

Malignant Primary Only for a person.

Cases diagnosed more than 28 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000).

Due to rounding, the sum of the age specific estimates may not equal the all ages estimate.

Table I-18 - continued US COMPLETE PREVALENCE COUNTS, INVASIVE CANCERS ONLY, JANUARY 1, 2003a BY AGE AT PREVALENCE

	Age Specific											
Age at Prevalence	All Ages ^c	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70+			
Gita (Gara												
<u>Site/Sex</u> Breast												
Males	12,241	0	12	0	138	501	2,018	3,220	6,352			
Females	2,356,795	0	58	1,897	35,796	202,103	463,141	551,858	1,101,941			
Cervix												
Females	253,781	0	12	2,238	19,634	45,855	54,849	48,649	82,544			
Corpus & Uterus, NOS												
Females	570,806	0	68	451	4,374	22,425	69,334	115,436	358,717			
Ovary ^d												
Females	171,840	57	1,036	2,924	7,728	21,508	35,022	38,235	65,331			
Prostate												
Males	1,937,798	34	69	102	287	14,311	158,820	480,773	1,283,404			
Urinary Bladder												
Males	372,313	28	168	630	2,626	13,116	40,053	82,767	232,925			
Females	133,452	11	34	312	1,451	4,424	12,280	25,854	89,087			
Kidney & Renal Pelvis												
Males	136,080	1,562	2,410	1,944	3,920	12,023	25,151	34,383	54,686			
Females	94,068	1,692	2,445	2,393	3,237	8,407	14,562	20,318	41,015			
Hodgkin Lymphoma												
Males	76,517	175	1,937	8,639	17,052	20,887	15,363	7,794	4,669			
Females	70,870	78	1,774	8,645	17,642	19,549	13,169	5,097	4,917			
Non-Hodgkin Lymphoma												
Males	189,637	628	3,276	5,999	11,545	24,272	37,160	41,448	65,309			
Females	174,848	318	1,345	3,202	7,858	16,562	29,315	36,241	80,005			
Myeloma												
Males	28,818	0	5	17	532	1,989	6,003	7,918	12,354			
Females	23,112	0	0	33	229	1,199	4,167	5,911	11,573			
Leukemia												
Males	112,324	5,971	10,583	8,752	7,749	9,840	14,402	19,623	35,403			
Females	86,689	4,951	8,862	8,196	5,790	6,752	9,025	12,414	30,700			
Acute Lymphocytic Leuk												
Males	28,078	5,125	9,066	6,824	4,440	1,343	635	402	243			
Females	22,861	4,345	7,539	5,903	2,846	1,161	567	236	263			

US 2003 cancer prevalence counts are based on 2003 cancer prevalence proportions from the SEER 9 registries (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta) and 1/1/2003 US population estimates based on the average of 2002 and 2003 population estimates from the US Bureau of the Census. Prevalence was calculated using the First Malignant Primary Only for a person.

d Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

Cases diagnosed more than 28 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000).

Due to rounding, the sum of the age specific estimates may not equal the all ages estimate.

Table II-16 ALL SITES (Invasive)

Estimated United States Cancer Prevalence Counts^a on January 1, 2003 By Race/Ethnicity, Sex and Years Since Diagnosis

Years Since Diagnosis	0 to <5	5 to <10	10 to <15	15 to <20	20 to <25	0 to <13 ^e	0 to <28 ^e	>=28 ^g	Completeh
Race/Sex									
All Races ^b	3,962,252	2,511,031	1,605,669	924,744	564,549	7,559,653	9,822,273	673,712	10,495,985
Males	2,012,274	1,244,498	717,207	332,858	179,942	3,770,369	4,554,140	138,242	4,692,382
Females	1,949,978	1,266,533	888,462	591,886	384,607	3,789,284	5,268,133	535,470	5,803,603
White ^b	3,442,564	2,213,728	1,450,941	842,073	516,600	6,635,621	8,698,301	596,996	9,295,297
Males	1,736,715	1,087,998	650,645	304,446	166,160	3,288,860	4,008,076	127,969	4,136,045
Females	1,705,849	1,125,730	800,296	537,627	350,440	3,346,761	4,690,225	469,027	5,159,252
Black ^b	361,605	208,112	107,160	55,249	32,825	643,940	779,028	37,221	816,249
Males	196,730	114,039	47,712	18,925	9,172	346,414	389,648	4,256	393,904
Females	164,875	94,073	59,448	36,324	23,653	297,526	389,380	32,965	422,345
Asian/Pacific Islander ^c	89,637	48,904	+	+	+	157,208	+	+	+
Males	39,159	20,104	+	+	+	66,122	+	+	+
Females	50,478	28,800	+	+	+	91,086	+	+	+
Hispanic ^d	197,915	110,621	+	+	+	354,861	+	+	+
Males	96,036	52,006	+	+	+	167,076	+	+	+
Females	101,879	58,615	+	+	+	187,785	+	+	+

Estimated prevalence percent^a on January 1, 2003, of the SEER 11 population diagnosed in the previous 10 years By Age at Prevalence, Race/Ethnicity and Sex

	Age Specific (Crude)										Age-Adjustedf
Age at Prevalence	All Ages	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70-79	80+	All Ages
Race/Sex All Races ^c	1.9814%	0.0768%	0.1062%	0.2104%	0.5283%	1.2572%	3.0482%	6.6866%	10.6455%	10.0716%	2.1199%
Males Females	1.9956%	0.0703% 0.0805% 0.0729%	0.1002% 0.1135% 0.0985%	0.21048 0.19438 0.22738	0.4104% 0.6497%	0.8423% 1.6678%	2.5543% 3.5165%	7.7010% 5.7819%	14.6841%	14.4892%	2.4448% 1.9260%
White ^c	2.1570%	0.0830%	0.1160%	0.2329%	0.5747%	1.3185%	3.1557%	6.9973%	11.0680%	10.2418%	2.2061%
Males	2.1418%	0.0868%	0.1238%	0.2155%	0.4544%	0.8883%	2.6042%	7.8891%	14.9232%	14.4624%	2.4951%
Females	2.1721%	0.0790%	0.1078%	0.2517%	0.7036%	1.7581%	3.6939%	6.1814%	8.1122%	7.9806%	2.0416%
Black ^c	1.4627%	0.0494%	0.0718%	0.1362%	0.3876%	1.0606%	3.0732%	7.0856%	10.6798%	8.7713%	2.0473%
Males	1.6751%	0.0478%	0.0767%	0.1203%	0.2747%	0.7684%	3.2879%	10.0411%	17.5713%	14.6300%	2.8295%
Females	1.2704%	0.0512%	0.0668%	0.1510%	0.4875%	1.3167%	2.8952%	4.7686%	6.1511%	5.9829%	1.5501%
Asian/Pacific Islander	1.2518%	0.0626%	0.0804%	0.1312%	0.3326%	0.9321%	2.0757%	3.8570%	6.7205%	7.6464%	1.3969%
Males	1.1453%	0.0694%	0.0867%	0.1168%	0.2069%	0.4809%	1.2944%	3.8179%	9.2331%	10.9872%	1.4822%
Females	1.3516%	0.0555%	0.0736%	0.1455%	0.4515%	1.3396%	2.7596%	3.8896%	4.9006%	5.3938%	1.3718%
Hispanic ^d	0.7866%	0.0716%	0.0954%	0.1401%	0.3580%	0.8862%	2.0074%	4.3784%	7.5976%	7.2520%	1.4755%
Males	0.7218%	0.0740%	0.1034%	0.1292%	0.2591%	0.4908%	1.4776%	5.0627%	11.1673%	11.1041%	1.7353%
Females	0.8547%	0.0692%	0.0869%	0.1529%	0.4705%	1.2922%	2.4962%	3.8135%	5.0495%	5.0865%	1.3425%

US 2003 cancer prevalence counts are based on 2003 cancer prevalence proportions from the SEER registries and 1/1/2003 US population estimates based on the average of 2002 and 2003 population estimates from the US Bureau of the Census. Prevalence was calculated using the First Malignant Primary Only for a person.

Statistics based on (b) SEER 9 Areas (c) SEER 11 Areas and Rural Georgia (d) NHIA for Hispanic for SEER 11 Areas and Rural Georgia excluding Hawaii and Seattle.

Maximum limited-duration prevalence: 28 years for 1975-2003 SEER 9 data; 13 years for 1990-2003 SEER 11 data (used to calculate prevalence for Hispanics and Asian Pacific Islanders).

g h

Percentages are age-adjusted to the 2000 US standard population by 5-year age groups.

(g) Cases diagnosed more than 28 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000). (h)Complete prevalence is obtained by summing 0 to <28 and >=28.

Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

bcd

Table III-16 BRAIN AND OTHER NERVOUS SYSTEM (Invasive)

Estimated United States Cancer Prevalence Counts^a on January 1, 2003 By Race/Ethnicity, Sex and Years Since Diagnosis

Years Since Diagnosis	0 to <5	5 to <10	10 to <15	15 to <20	20 to <25	0 to <13 ^e	0 to <28 ^e	>=28 ^g	Completeh
Race/Sex	0.5.404	04 505	4.6.400	44 045		50 401	06 500	4.4 = 0.4	
All Races ^b	37,131	21,585	16,423	11,015	6,875	69,491	96,508	14,704	111,212
Males	19,885	12,053	8,963	5,774	3,594	37,996	51,982	6,768	58,750
Females	17,246	9,532	7,460	5,241	3,281	31,495	44,526	7,936	52,462
White ^b	33,036	19,007	14,466	9,874	6,117	61,485	85,639	9,218	94,857
Males	17,826	10,671	7,872	5,109	3,222	33,805	46,256	4,790 ⁱ	51,046
Females	15,210	8,336	6,594	4,765	2,895	27,680	39,383	$4,428^{i}$	43,811
Black ^b	2,656	1,693	1,413	822	575	5,283	7,410	+	+
Males	1,382	887	769	468	296	2,784	3,909	+	+
Females	1,274	806	644	354	279	2,499	3,501	+	+
Asian/Pacific Islander ^c	860	528	+	+	+	1,608	+	+	+
Males	425	274	+	+	+	833	+	+	+
Females	435	254	+	+	+	775	+	+	+
Hispanic ^d	3,380	1,642	+	+	+	5,891	+	+	+
Males	1,712	860	+	+	+	3,030	+	+	+
Females	1,668	782	+	+	+	2,861	+	+	+

Estimated prevalence percent on January 1, 2003, of the SEER 11 population diagnosed in the previous 10 years By Age at Prevalence, Race/Ethnicity and Sex

	Age Specific (Crude)										Age-Adjustedf
Age at Prevalence	All Ages	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70-79	80+	All Ages
Race/Sex	0.0185%	0.0136%	0.0199%	0.0149%	0.0189%	0.0225%	0.0221%	0.0206%	0.0191%	0.0103%	0.0186%
All Races ^c Males Females	0.0185% 0.0203% 0.0168%	0.0138% 0.0133%	0.0199% 0.0219% 0.0178%	0.0149% 0.0162% 0.0135%	0.0189% 0.0202% 0.0177%	0.0248% 0.0202%	0.0245% 0.0199%	0.0208% 0.0233% 0.0181%	0.0191% 0.0232% 0.0160%	0.0103% 0.0124% 0.0091%	0.01888 0.02048 0.01688
White ^c	0.0207%	0.0152%	0.0215%	0.0164%	0.0215%	0.0260%	0.0246%	0.0232%	0.0208%	0.0104%	0.0207%
Males	0.0227%	0.0155%	0.0238%	0.0178%	0.0223%	0.0283%	0.0270%	0.0272%	0.0256%	0.0132%	0.0227%
Females	0.0187%	0.0149%	0.0191%	0.0149%	0.0205%	0.0237%	0.0223%	0.0195%	0.0171%	0.0089%	0.0189%
Black ^c	0.0115%	0.0095%	0.0142%	0.0105%	0.0108%	0.0101%	0.0149%	0.0099%	0.0135%	0.0096%	0.0115%
Males	0.0125%	0.0090%	0.0156%	0.0121%	0.0125%	0.0131%	0.0174%	0.0058%	0.0137%	-	0.0123%
Females	0.0105%	0.0099%	0.0127%	0.0091%	0.0093%	0.0076%	0.0129%	0.0132%	0.0135%	0.0124%	0.0107%
Asian/Pacific Islander	0.0106%	0.0069%	0.0158%	0.0091%	0.0115%	0.0109%	0.0100%	0.0108%	0.0109%	0.0071%	0.0107%
Males	0.0110%	0.0073%	0.0166%	0.0094%	0.0123%	0.0108%	0.0110%	0.0074%	0.0132%	-	0.0112%
Females	0.0103%	0.0065%	0.0149%	0.0088%	0.0107%	0.0110%	0.0091%	0.0136%	0.0092%	-	0.0103%
Hispanic ^d	0.0130%	0.0105%	0.0129%	0.0081%	0.0133%	0.0193%	0.0185%	0.0166%	0.0186%	0.0070%	0.0140%
Males	0.0129%	0.0096%	0.0135%	0.0080%	0.0124%	0.0210%	0.0206%	0.0148%	0.0157%	-	0.0141%
Females	0.0131%	0.0114%	0.0123%	0.0082%	0.0143%	0.0176%	0.0165%	0.0180%	0.0206%	-	0.0140%

bcd

f

US 2003 cancer prevalence counts are based on 2003 cancer prevalence proportions from the SEER registries and 1/1/2003 US population estimates based on the average of 2002 and 2003 population estimates from the US Bureau of the Census. Prevalence was calculated using the First Malignant Primary Only for a person.

Statistics based on (b) SEER 9 Areas (c) SEER 11 Areas and Rural Georgia (d) NHIA for Hispanic for SEER 11 Areas and Rural Georgia excluding Hawaii and Seattle.

Maximum limited-duration prevalence: 28 years for 1975-2003 SEER 9 data; 13 years for 1990-2003 SEER 11 data (used to calculate prevalence for Hispanics and Asian Pacific Islanders).

Percentages are age-adjusted to the 2000 US standard population by 5-year age groups.

(g) Cases diagnosed more than 28 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000). (h)Complete prevalence is obtained by summing 0 to <28 and >=28. (i)Age-specific completeness index was approximated using empirical data from historical Connecticut tumor registry.

Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

Table IV-21 BREAST CANCER (Invasive)

Estimated United States Cancer Prevalence Counts^a on January 1, 2003 By Race/Ethnicity, Sex and Years Since Diagnosis

Years Since Diagnosis	0 to <5	5 to <10	10 to <15	15 to <20	20 to <25	0 to <13 ^e	0 to <28 ^e	>=28 ^g	Complete ^h
Race/Sex									
All Races ^b	827,910	579,192	402,323	243,275	134,102	1,667,841	2,248,621	120,415	2,369,036
Males	5,301	2,924	1,765	1,029	649	9,423	11,891	350	12,241
Females	822,609	576,268	400,558	242,246	133,453	1,658,418	2,236,730	120,065	2,356,795
	,	•	•	•	•		•	•	
White ^b	727,023	516,929	364,149	222,225	122,488	1,479,005	2,009,600	107,266	2,116,866
Males	4,530	2,579	1,538	945	600	8,153	10,414	234¹	10,648
Females	722,493	514,350	362,611	221,280	121,888	1,470,852	1,999,186	107,032	2,106,218
Black ^b	69,349	44,140	27,447	15,249	8,547	131,694	168,338	+	+
Males	615	244	199	72	45	995	1,176		
				. –				0 252	175 /15
Females	68,734	43,896	27,248	15,177	8,502	130,699	167,162	8,253	175,415
Asian/Pacific Islander ^c	21,783	12,976	+	+	+	40,018	+	+	+
Males	70	69	+	+	+	158	+	+	+
Females	21,713	12,907	+	+	+	39,860	+	+	+
Hispanic ^d	38,515	23,206	+	+	+	72,065	+	+	+
	146	54			•	225			
Males			+	+	+		+	+	+
Females	38,369	23,152	+	+	+	71,840	+	+	+

Estimated prevalence percent on January 1, 2003, of the SEER 11 population diagnosed in the previous 10 years By Age at Prevalence, Race/Ethnicity and Sex

_	Age Specific (Crude)									Age-Adjustedf	
Age at Prevalence	All Ages	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70-79	80+	All Ages
Race/Sex											
All Races ^c	0.4362%	_	0.0002%	0.0047%	0.0763%	0.3791%	0.9425%	1.4571%	1.8827%	2.0176%	0.4597%
Males	0.0051%	_	-	_	0.0006%	0.0023%	0.0089%	0.0214%	0.0318%	0.0404%	0.0063%
Females	0.8576%	-	0.0003%	0.0096%	0.1543%	0.7519%	1.8276%	2.7377%	3.2761%	3.0921%	0.8390%
White	0.4792%	_	0.0002%	0.0044%	0.0748%	0.3861%	0.9803%	1.5544%	2.0198%	2.1429%	0.4837%
Males	0.0054%	_	-	-	0.0005%	0.0022%	0.0088%	0.0209%	0.0339%	0.0421%	0.0063%
Females	0.9507%	_	0.0004%	0.0092%	0.1544%	0.7784%	1.9283%	2.9576%	3.5424%	3.2685%	0.8912%
Black ^c	0.2983%	_	-	0.0060%	0.0912%	0.3584%	0.8359%	1.2034%	1.5611%	1.6053%	0.3974%
Males	0.0053%	_	-	_	_	0.0038%	0.0147%	0.0346%	0.0373%	0.0411%	0.0086%
Females	0.5637%	_	-	0.0115%	0.1713%	0.6691%	1.5167%	2.1197%	2.5625%	2.3498%	0.6852%
Asian/Pacific Islander	0.3044%	-	_	0.0050%	0.0707%	0.3514%	0.7668%	1.0047%	1.1252%	1.0712%	0.3263%
Males	0.0026%	_	-	-	_	0.0020%	0.0032%	0.0127%	0.0129%	0.0259%	0.0033%
Females	0.5870%	-	-	0.0100%	0.1370%	0.6669%	1.4352%	1.8309%	1.9309%	1.7760%	0.5909%
Hispanic ^d	0.1603%	_	_	0.0033%	0.0492%	0.2684%	0.6170%	0.9176%	1.1655%	1.2187%	0.2959%
Males	0.0010%	_	-	_	_	0.0014%	0.0026%	0.0082%	0.0108%	0.0162%	0.0024%
Females	0.3276%	_	_	0.0072%	0.1049%	0.5425%	1.1839%	1.6683%	1.9897%	1.8948%	0.5367%

- US 2003 cancer prevalence counts are based on 2003 cancer prevalence proportions from the SEER registries and 1/1/2003 US population estimates based on the average of 2002 and 2003 population estimates from the US Bureau of the Census. Prevalence was calculated using the First Malignant Primary Only for a person.

 Statistics based on (b) SEER 9 Areas (c) SEER 11 Areas and Rural Georgia (d) NHIA for Hispanic for SEER 11 Areas and Rural Georgia excluding Hawaii and Seattle.
- bcd
- f
- Georgia excluding Hawaii and Seattle.

 Maximum limited-duration prevalence: 28 years for 1975-2003 SEER 9 data; 13 years for 1990-2003 SEER 11 data (used to calculate prevalence for Hispanics and Asian Pacific Islanders).

 Percentages are age-adjusted to the 2000 US standard population by 5-year age groups.

 (g) Cases diagnosed more than 28 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000). (h)Complete prevalence is obtained by summing 0 to <28 and >=28. (i)Age-specific completeness index was approximated using empirical data from historical Connecticut tumor registry. ghi
- Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

Table V-12 CERVIX UTERI CANCER (Invasive)

Estimated United States Cancer Prevalence Counts^a on January 1, 2003 By Race/Ethnicity and Years Since Diagnosis

Years Since Diagnosis	0 to <5	5 to <10	10 to <15	15 to <20	20 to <25	0 to <13 ^e	0 to <28 ^e	>=28 ^g	Complete ^h
<u>Race</u> All Races ^b	43,374	39,886	35,352	27,575	23,494	104,742	183,935	69,846	253,781
White ^b	34,102	31,874	29,343	22,930	19,214	83,766	149,163	58,118	207,281
Black ^b	6,519	5,160	4,102	3,370	3,258	14,208	24,512	+	+
Asian/Pacific Islander ^c	1,969	1,732	+	+	+	4,466	+	+	+
Hispanic ^d	8,038	6,101	+	+	+	17,529	+	+	+

Estimated prevalence percent on January 1, 2003, of the SEER 11 population diagnosed in the previous 10 years By Age at Prevalence and Race/Ethnicity

	Age Specific (Crude)									Age-Adjustedf	
Age at Prevalence	All Ages	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70-79	80+	All Ages
<u>Race</u>											
All Races ^c	0.0611%	-	-	0.0103%	0.0767%	0.1223%	0.1166%	0.1094%	0.0937%	0.0606%	0.0605%
White ^c	0.0611%	-	-	0.0114%	0.0855%	0.1274%	0.1121%	0.0963%	0.0806%	0.0460%	0.0601%
Black ^c	0.0576%	-	-	0.0093%	0.0637%	0.1080%	0.1184%	0.1416%	0.1358%	0.1607%	0.0646%
Asian/Pacific Islande	r ^c 0.0608%	-	-	0.0034%	0.0337%	0.0962%	0.1362%	0.1614%	0.1498%	0.1176%	0.0601%
Hispanic ^d	0.0758%	_	-	0.0115%	0.0906%	0.2025%	0.2212%	0.2069%	0.2338%	0.1217%	0.1046%

bcd

f

US 2003 cancer prevalence counts are based on 2003 cancer prevalence proportions from the SEER registries and 1/1/2003 US population estimates based on the average of 2002 and 2003 population estimates from the US Bureau of the Census. Prevalence was calculated using the First Malignant Primary Only for a person.

Statistics based on (b) SEER 9 Areas (c) SEER 11 Areas and Rural Georgia (d) NHIA for Hispanic for SEER 11 Areas and Rural Georgia excluding Hawaii and Seattle.

Maximum limited-duration prevalence: 28 years for 1975-2003 SEER 9 data; 13 years for 1990-2003 SEER 11 data (used to calculate prevalence for Hispanics and Asian Pacific Islanders).

Percentages are age-adjusted to the 2000 US standard population by 5-year age groups.

(g) Cases diagnosed more than 28 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000). (h)Complete prevalence is obtained by summing 0 to <28 and >=28. (i)Age-specific completeness index was approximated using empirical data from historical Connecticut tumor registry.

Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval. ghi

Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

Table VI-23 COLON AND RECTUM CANCER (Invasive)

Estimated United States Cancer Prevalence Counts^a on January 1, 2003 By Race/Ethnicity, Sex and Years Since Diagnosis

Years Since Diagnosis	0 to <5	5 to <10	10 to <15	15 to <20	20 to <25	0 to <13 ^e	0 to <28 ^e	>=28 ^g	Complete ^h
Race/Sex									
All Races ^b	416,089	238,065	165,688	108,697	61,523	762,462	1,012,722	55,476	1,068,198
Males	207,662	117,724	82,105	52,008	25,932	379,236	494,463	20,326	514,789
Females	208,427	120,341	83,583	56,689	35,591	383,226	518,259	35,150	553,409
White ^b	358,288	208,250	146,687	97,237	55,369	662,584	886,271	49,625	935,896
Males	180,179	103,668	73,262	46,809	23,467	331,729	435,544	18,337	453,881
Females	178,109	104,582	73,425	50,428	31,902	330,855	450,727	31,288	482,015
Black ^b	39,757	20,776	13,531	8,332	4,347	69,195	88,244	3,816	92,060
Males	17,689	9,203	5,991	3,451	1,585	30,968	38,475	1,289	39,764
Females	22,068	11,573	7,540	4,881	2,762	38,227	49,769	2,527	52,296
Asian/Pacific Islander ^c	12,355	6,306	+	+	+	21,142	+	+	+
Males	6,533	3,376	+	+	+	11,139	+	+	+
Females	5,822	2,930	+	+	+	10,003	+	+	+
Hispanic ^d	18,538	9,092	+	+	+	31,876	+	+	+
Males	10,067	4,834	+	+	+	17,043	+	+	+
Females	8,471	4,258	+	+	+	14,833	+	+	+

Estimated prevalence percent on January 1, 2003, of the SEER 11 population diagnosed in the previous 10 years By Age at Prevalence, Race/Ethnicity and Sex

_	Age Specific (Crude)										
Age at Prevalence	All Ages	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70-79	80+	All Ages
Race/Sex											
All Races ^c	0.2008%	-	0.0002%	0.0036%	0.0192%	0.0718%	0.2483%	0.6476%	1.2394%	1.6585%	0.2179%
Males	0.2037%	_	0.0002%	0.0036%	0.0201%	0.0748%	0.2828%	0.7802%	1.4976%	1.8458%	0.2544%
Females	0.1980%	_	0.0003%	0.0035%	0.0183%	0.0689%	0.2156%	0.5293%	1.0450%	1.5567%	0.1896%
White ^c	0.2122%	_	0.0003%	0.0033%	0.0186%	0.0684%	0.2366%	0.6446%	1.2561%	1.6855%	0.2174%
Males	0.2140%	_	0.0002%	0.0034%	0.0193%	0.0713%	0.2717%	0.7812%	1.5130%	1.8739%	0.2541%
Females	0.2105%	_	0.0003%	0.0033%	0.0178%	0.0655%	0.2024%	0.5196%	1.0592%	1.5846%	0.1883%
Black ^c	0.1552%	_	_	0.0038%	0.0186%	0.0871%	0.3176%	0.7551%	1.2116%	1.4315%	0.2275%
Males	0.1470%	_	_	0.0031%	0.0180%	0.0895%	0.3580%	0.8357%	1.3377%	1.4488%	0.2473%
Females	0.1626%	_	_	0.0044%	0.0192%	0.0850%	0.2841%	0.6919%	1.1288%	1.4233%	0.2135%
Asian/Pacific Islander	0.1760%	_	_	0.0044%	0.0219%	0.0775%	0.2564%	0.5698%	1.1153%	1.5422%	0.2039%
Males	0.1918%	_	_	0.0054%	0.0259%	0.0835%	0.2851%	0.7035%	1.4523%	1.8013%	0.2480%
Females	0.1611%	_	-	0.0033%	0.0181%	0.0720%	0.2312%	0.4584%	0.8712%	1.3675%	0.1708%
Hispanic ^d	0.0700%	_	_	0.0032%	0.0147%	0.0482%	0.1741%	0.4576%	0.8753%	1.0560%	0.1508%
Males	0.0726%	_	_	0.0035%	0.0149%	0.0468%	0.1971%	0.5863%	1.1661%	1.2298%	0.1856%
Females	0.0673%	_	_	0.0027%	0.0145%	0.0496%	0.1529%	0.3513%	0.6677%	0.9583%	0.1251%

US 2003 cancer prevalence counts are based on 2003 cancer prevalence proportions from the SEER registries and 1/1/2003 US population estimates based on the average of 2002 and 2003 population estimates from the US Bureau of the Census. Prevalence was calculated using the First Malignant Primary Only for a person.

Statistics based on (b) SEER 9 Areas (c) SEER 11 Areas and Rural Georgia (d) NHIA for Hispanic for SEER 11 Areas and Rural Georgia excluding Hawaii and Seattle.

Maximum limited-duration prevalence: 28 years for 1975-2003 SEER 9 data; 13 years for 1990-2003 SEER 11 data (used to calculate prevalence for Hispanics and Asian Pacific Islanders).

g h

Percentages are age-adjusted to the 2000 US standard population by 5-year age groups.

(g) Cases diagnosed more than 28 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000). (h)Complete prevalence is obtained by summing 0 to <28 and >=28.

Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

bcd

Table VII-12 CORPUS AND UTERUS, NOS CANCER (Invasive)

Estimated United States Cancer Prevalence Counts^a on January 1, 2003 By Race/Ethnicity and Years Since Diagnosis

Years Since Diagnosis	0 to <5	5 to <10	10 to <15	15 to <20	20 to <25	0 to <13 ^e	0 to <28 ^e	>=28 ^g	Complete ^h
<u>Race</u> All Races ^b	144,051	108,706	84,065	65,398	55,176	306,527	493,698	77,108	570,806
White ^b	128,689	99,769	78,690	61,867	52,434	278,882	456,178	68,721	524,899
Black ^b	9,210	4,884	3,146	2,050	1,464	16,010	21,528	1,581	23,109
Asian/Pacific Islander ^c	3,665	2,327	+	+	+	6,903	+	+	+
Hispanic ^d	6,643	4,280	+	+	+	13,160	+	+	+

Estimated prevalence percent on January 1, 2003, of the SEER 11 population diagnosed in the previous 10 years By Age at Prevalence and Race/Ethnicity

	Age Specific (Crude)										
Age at Prevalence	All Ages	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70-79	+08	All Ages
Race	0 15100		0.00008	0 00038	0.00048	0.00208	0 00408	0 50078	0.66000	0 55520	0 14000
All Races ^c	0.1512%	_	0.0002%	0.0023%	0.0204%	0.0839%	0.2840%	0.5887%	0.6698%	0.5553%	0.1489%
White ^c	0.1722%	-	-	0.0018%	0.0196%	0.0840%	0.3051%	0.6545%	0.7474%	0.6042%	0.1620%
Black ^c	0.0691%	-	-	0.0030%	0.0190%	0.0503%	0.1328%	0.3679%	0.4185%	0.2934%	0.0876%
Asian/Pacific Islande	er ^c 0.1009%	=	-	0.0034%	0.0226%	0.1083%	0.2692%	0.3314%	0.3053%	0.2504%	0.1010%
Hispanic ^d	0.0580%	_	_	0.0029%	0.0238%	0.0744%	0.2041%	0.3554%	0.3665%	0.2682%	0.0949%

Percentages are age-adjusted to the 2000 US standard population by 5-year age groups.

(g) Cases diagnosed more than 28 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000). (h)Complete prevalence is obtained by summing 0 to <28 and >=28.

Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

US 2003 cancer prevalence counts are based on 2003 cancer prevalence proportions from the SEER registries and 1/1/2003 US population estimates based on the average of 2002 and 2003 population estimates from the US Bureau of the Census. Prevalence was calculated using the First Malignant Primary Only for a person.

Statistics based on (b) SEER 9 Areas (c) SEER 11 Areas and Rural Georgia (d) NHIA for Hispanic for SEER 11 Areas and Rural Georgia excluding Hawaii and Seattle.

Maximum limited-duration prevalence: 28 years for 1975-2003 SEER 9 data; 13 years for 1990-2003 SEER 11 data (used to calculate prevalence for Hispanics and Asian Pacific Islanders).

bcd

g h

Table VIII-16 ESOPHAGUS CANCER (Invasive)

Estimated United States Cancer Prevalence Counts^a on January 1, 2003 By Race/Ethnicity, Sex and Years Since Diagnosis

Years Since Diagnosis	0 to <5	5 to <10	10 to <15	15 to <20	20 to <25	0 to <13 ^e	0 to <28 ^e	>=28 ^g	Complete ^h
Race/Sex									
All Races ^b	16,590	4,363	1,804	674	271	22,336	23,825	240	24,065
Males	12,747	3,273	1,236	425	210	16,955	17,985	119	18,104
Females	3,843	1,090	568	249	61	5,381	5,840	121	5,961
White ^b	14,345	3,867	1,427	594	222	19,327	20,552	199	20,751
Males	11,238	2,932	1,005	373	188	14,922	15,818	112	15,930
Females	3,107	935	422	221	34	4,405	4,734	87	4,821
Black ^b	1,751	438	314	77	40	2,417	2,648	63	2,711
Males	1,162	290	187	52	14	1,604	1,719	19	1,738
Females	589	148	127	25	26	813	929	44	973
Asian/Pacific Islander ^c	276	66	+	+	+	374	+	+	+
Males	199	51	+	+	+	275	+	+	+
Females	77	15	+	+	+	99	+	+	+
Hispanic ^d	566	153	+	+	+	776	+	+	+
Males	442	114	+	+	+	608	+	+	+
Females	124	39	+	+	+	168	+	+	+

Estimated prevalence percent^a on January 1, 2003, of the SEER 11 population diagnosed in the previous 10 years By Age at Prevalence, Race/Ethnicity and Sex

_	Age Specific (Crude)										
Age at Prevalence	All Ages	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70-79	80+	All Ages
Race/Sex											
All Races ^c	0.0060%	-	-	0.0001%	0.0004%	0.0025%	0.0110%	0.0250%	0.0347%	0.0267%	0.0065%
Males	0.0092%	-	-	0.0002%	0.0007%	0.0040%	0.0187%	0.0417%	0.0596%	0.0460%	0.0109%
Females	0.0029%	_	-	-	-	0.0011%	0.0037%	0.0101%	0.0161%	0.0161%	0.0028%
White ^c	0.0066%	-	-	0.0001%	0.0004%	0.0026%	0.0116%	0.0260%	0.0365%	0.0281%	0.0068%
Males	0.0101%	_	-	-	0.0007%	0.0041%	0.0202%	0.0436%	0.0631%	0.0479%	0.0115%
Females	0.0030%	-	-	-	-	0.0010%	0.0031%	0.0100%	0.0161%	0.0175%	0.0028%
Black ^c	0.0053%	-	-	_	_	0.0037%	0.0134%	0.0321%	0.0363%	0.0217%	0.0074%
Males	0.0074%	-	_	_	_	0.0054%	0.0198%	0.0484%	0.0564%	0.0411%	0.0115%
Females	0.0035%	_	-	-	_	0.0022%	0.0081%	0.0192%	0.0231%	0.0124%	0.0045%
Asian/Pacific Islander	0.0032%	_	_	_	_	0.0010%	0.0054%	0.0123%	0.0211%	0.0184%	0.0036%
Males	0.0048%	-	_	_	_	0.0015%	0.0074%	0.0221%	0.0362%	0.0367%	0.0060%
Females	0.0016%	_	-	-	_	_	0.0035%	0.0042%	0.0102%	-	0.0017%
Hispanic ^d	0.0018%	_	_	_	_	0.0013%	0.0056%	0.0129%	0.0207%	0.0219%	0.0038%
Males	0.0027%	_	_	-	_	0.0020%	0.0101%	0.0225%	0.0379%	0.0317%	0.0065%
Females	0.0009%	-	-	_	-	-	-	0.0049%	0.0084%	0.0164%	0.0017%

US 2003 cancer prevalence counts are based on 2003 cancer prevalence proportions from the SEER registries and 1/1/2003 US population estimates based on the average of 2002 and 2003 population estimates from the US Bureau of the Census. Prevalence was calculated using the First Malignant Primary Only for a person.

Statistics based on (b) SEER 9 Areas (c) SEER 11 Areas and Rural Georgia (d) NHIA for Hispanic for SEER 11 Areas and Rural Georgia excluding Hawaii and Seattle.

Maximum limited-duration prevalence: 28 years for 1975-2003 SEER 9 data; 13 years for 1990-2003 SEER 11 data (used to calculate prevalence for Hispanics and Asian Pacific Islanders).

g h

Percentages are age-adjusted to the 2000 US standard population by 5-year age groups.

(g) Cases diagnosed more than 28 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000). (h)Complete prevalence is obtained by summing 0 to <28 and >=28.

Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

bcd

Table IX-16 HODGKIN LYMPHOMA (Invasive)

Estimated United States Cancer Prevalence Counts^a on January 1, 2003 By Race/Ethnicity, Sex and Years Since Diagnosis

Years Since Diagnosis	0 to <5	5 to <10	10 to <15	15 to <20	20 to <25	0 to <13 ^e	0 to <28 ^e	>=28 ^g	Complete
Race/Sex									
All Races ^b	33,724	28,743	25,918	20,678	14,936	78,423	131,045	16,342	147,387
Males	17,816	14,921	13,249	10,740	7,865	41,005	68,125	8,392	76,517
Females	15,908	13,822	12,669	9,938	7,071	37,418	62,920	7,950	70,870
White ^b	28,911	25,463	23,618	19,112	13,917	68,777	117,674	18,256	135,930
Males	15,273	13,302	12,157	9,797	7,231	36,097	60,992	9,474	70,466
Females	13,638	12,161	11,461	9,315	6,686	32,680	56,682	8,782	65,464
Black ^b	3,536	2,729	1,844	1,260	867	7,539	10,543	1,241	11,784
Males	1,797	1,338	852	765	559	3,734	5,557	843	6,400
Females	1,739	1,391	992	495	308	3,805	4,986	398	5,384
Asian/Pacific Islander ^c	604	289	+	+	+	1,050	+	+	+
Males	326	137	+	+	+	537	+	+	+
Females	278	152	+	+	+	513	+	+	+
Hispanic ^d	2,781	1,855	+	+	+	5,551	+	+	+
Males	1,628	1,001	+	+	+	3,167	+	+	+
Females	1,153	854	+	+	+	2,384	+	+	+

Estimated prevalence percent^a on January 1, 2003, of the SEER 11 population diagnosed in the previous 10 years By Age at Prevalence, Race/Ethnicity and Sex

	Age Specific (Crude)										
Age at Prevalence	All Ages	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70-79	+08	All Ages
Race/Sex											
All Races ^c	0.0196%	0.0008%	0.0082%	0.0306%	0.0351%	0.0257%	0.0182%	0.0187%	0.0172%	0.0110%	0.0194%
Males	0.0210%	0.0012%	0.0084%	0.0286%	0.0357%	0.0290%	0.0219%	0.0235%	0.0212%	0.0139%	0.0209%
Females	0.0210%	0.0012%	0.0079%	0.0280%	0.0346%	0.0236%	0.0219%	0.0235%	0.0212%	0.0139%	0.0181%
White ^c	0.0220%	0.0009%	0.0095%	0.0348%	0.0397%	0.0286%	0.0201%	0.0210%	0.0190%	0.0117%	0.0218%
Males	0.0234%	0.0014%	0.0097%	0.0319%	0.0399%	0.0319%	0.0239%	0.0260%	0.0224%	0.0146%	0.0231%
Females	0.0205%	0.0004%	0.0092%	0.0379%	0.0394%	0.0251%	0.0165%	0.0164%	0.0164%	0.0102%	0.0206%
Black ^c	0.0170%	0.0009%	0.0049%	0.0263%	0.0328%	0.0248%	0.0185%	0.0156%	0.0123%	0.0060%	0.0172%
Males	0.0181%	-	0.0043%	0.0254%	0.0326%	0.0289%	0.0226%	0.0215%	0.0199%	-	0.0191%
Females	0.0161%	-	0.0055%	0.0271%	0.0329%	0.0212%	0.0151%	0.0110%	0.0072%	-	0.0157%
Asian/Pacific Islander	0.0068%	-	0.0041%	0.0111%	0.0105%	0.0077%	0.0043%	0.0066%	0.0083%	0.0075%	0.0066%
Males	0.0073%	-	0.0051%	0.0107%	0.0105%	0.0082%	0.0048%	0.0084%	0.0140%	-	0.0073%
Females	0.0063%	-	0.0030%	0.0114%	0.0106%	0.0074%	0.0039%	0.0051%	0.0042%	-	0.0059%
Hispanic ^d	0.0119%	0.0013%	0.0082%	0.0166%	0.0174%	0.0139%	0.0160%	0.0218%	0.0185%	0.0084%	0.0130%
Males	0.0131%	0.0021%	0.0098%	0.0146%	0.0182%	0.0160%	0.0207%	0.0260%	0.0310%	-	0.0153%
Females	0.0107%	-	0.0065%	0.0190%	0.0165%	0.0117%	0.0116%	0.0184%	0.0096%	-	0.0112%

US 2003 cancer prevalence counts are based on 2003 cancer prevalence proportions from the SEER registries and 1/1/2003 US population estimates based on the average of 2002 and 2003 population estimates from the US Bureau of the Census. Prevalence was calculated using the First Malignant Primary Only for a person.

Statistics based on (b) SEER 9 Areas (c) SEER 11 Areas and Rural Georgia (d) NHIA for Hispanic for SEER 11 Areas and Rural Georgia excluding Hawaii and Seattle.

Maximum limited-duration prevalence: 28 years for 1975-2003 SEER 9 data; 13 years for 1990-2003 SEER 11 data (used to calculate prevalence for Hispanics and Asian Pacific Islanders).

g h

Percentages are age-adjusted to the 2000 US standard population by 5-year age groups.

(g) Cases diagnosed more than 28 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000). (h)Complete prevalence is obtained by summing 0 to <28 and >=28.

Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

bcd

Table X-13 KAPOSI SARCOMA (Invasive)

Estimated United States Cancer Prevalence Counts^a on January 1, 2003 By Race/Ethnicity, Sex and Years Since Diagnosis

Years Since Diagnosis	0 to <5	5 to <10	10 to <15	15 to <20	20 to <25	0 to <13 ^e	0 to <28 ^e	>=28 ^g	Completeh
Race/Sex									
All Races ^b	6,714	8,906	2,953	977	328	17,674	20,047	+	+
Males	6,074	8,513	2,733	924	254	16,443	18,586	+	+
Females	640	393	220	53	74	1,231	1,461	+	+
White ^b	4,656	7,180	2,448	824	269	13,535	15,524	+	+
Males	4,144	6,929	2,262	771	206	12,609	14,400	+	+
Females	512	251	186	53	63	926	1,124	+	+
Black ^b	1,569	1,261	278	76	25	3,030	3,209	+	+
Males	1,476	1,153	254	76	25	2,805	2,984	+	+
Females	93	108	24	0	0	225	225	+	+
Asian/Pacific Islanderc	96	90	+	+	+	201	+	+	+
Males	93	90	+	+	+	198	+	+	+
Females	3	0	+	+	+	3	+	+	+
Hispanic ^d	1,160	1,246	+	+	+	2,734	+	+	+
Males	1,063	1,227	+	+	+	2,585	+	+	+
Females	97	19	+	+	+	149	+	+	+

Estimated prevalence percent on January 1, 2003, of the SEER 11 population diagnosed in the previous 10 years By Age at Prevalence, Race/Ethnicity and Sex

_	Age Specific (Crude)										Age-Adjustedf
Age at Prevalence	All Ages	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70-79	80+	All Ages
Race/Sex											
All Races ^c	0.0062%	_	_	0.0009%	0.0091%	0.0168%	0.0092%	0.0046%	0.0055%	0.0117%	0.0062%
Males	0.0119%	_	_	0.0018%	0.0176%	0.0333%	0.0185%	0.0090%	0.0103%	0.0196%	0.0121%
Females	0.0007%	_	_	_	0.0004%	0.0005%	0.0004%	0.0007%	0.0019%	0.0075%	0.0006%
White ^c	0.0062%	-	-	0.0006%	0.0087%	0.0169%	0.0092%	0.0048%	0.0059%	0.0120%	0.0062%
Males	0.0118%	-	-	0.0012%	0.0164%	0.0330%	0.0182%	0.0092%	0.0109%	0.0202%	0.0118%
Females	0.0007%	-	_	-	0.0005%	0.0003%	0.0003%	0.0007%	0.0022%	0.0075%	0.0006%
Black ^c	0.0083%	_	_	0.0033%	0.0163%	0.0233%	0.0123%	0.0041%	_	0.0108%	0.0087%
Males	0.0165%	_	_	0.0066%	0.0342%	0.0479%	0.0257%	0.0084%	-	-	0.0175%
Females	0.0009%	_	_	_	_	0.0017%	_	_	_	0.0124%	0.0010%
Asian/Pacific Islander	0.0015%	_	=	=	0.0012%	0.0043%	0.0026%	0.0019%	_	0.0044%	0.0015%
Males	0.0031%	_	_	_	0.0026%	0.0090%	0.0055%	0.0035%	_	0.0109%	0.0032%
Females	_	-	_	-	_	_	_	_	_	_	_
Hispanic ^d	0.0062%	_	_	0.0010%	0.0126%	0.0195%	0.0095%	0.0055%	0.0121%	0.0268%	0.0082%
Males	0.0115%	_	_	0.0018%	0.0231%	0.0381%	0.0194%	0.0107%	0.0236%	0.0388%	0.0154%
Females	0.0006%	-	-	-	-	-	-	-	-	0.0200%	0.0012%

bcd

f

US 2003 cancer prevalence counts are based on 2003 cancer prevalence proportions from the SEER registries and 1/1/2003 US population estimates based on the average of 2002 and 2003 population estimates from the US Bureau of the Census. Prevalence was calculated using the First Malignant Primary Only for a person.

Statistics based on (b) SEER 9 Areas (c) SEER 11 Areas and Rural Georgia (d) NHIA for Hispanic for SEER 11 Areas and Rural Georgia excluding Hawaii and Seattle.

Maximum limited-duration prevalence: 28 years for 1975-2003 SEER 9 data; 13 years for 1990-2003 SEER 11 data (used to calculate prevalence for Hispanics and Asian Pacific Islanders).

Percentages are age-adjusted to the 2000 US standard population by 5-year age groups.

(g) Cases diagnosed more than 28 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000). (h)Complete prevalence is obtained by summing 0 to <28 and >=28. (i)Age-specific completeness index was approximated using empirical data from historical Connecticut tumor registry.

Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

Table XI-16 KIDNEY AND RENAL PELVIS CANCER (Invasive)

Estimated United States Cancer Prevalence Counts^a on January 1, 2003 By Race/Ethnicity, Sex and Years Since Diagnosis

Years Since Diagnosis	0 to <5	5 to <10	10 to <15	15 to <20	20 to <25	0 to <13 ^e	0 to <28 ^e	>=28 ^g	Completeh
									_
Race/Sex									
All Races ^b	94,596	54,994	34,094	19,580	10,987	172,117	218,509	11,639	230,148
Males	56,984	32,814	19,735	11,506	6,173	103,079	129,547	6,533	136,080
Females	37,612	22,180	14,359	8,074	4,814	69,038	88,962	5,106	94,068
White ^b	81,066	47,137	30,559	17,676	9,673	148,385	189,996	13,217	203,213
Males	49,232	28,539	17,909	10,523	5,557	89,782	113,889	6,446	120,335
Females	31,834	18,598	12,650	7,153	4,116	58,603	76,107	6,771	82,878
Black ^b	10,176	6,155	2,859	1,540	1,097	18,165	22,140	2,002	24,142
Males	5,565	3,281	1,452	767	518	9,829	11,739	711	12,450
Females	4,611	2,874	1,407	773	579	8,336	10,401	1,291	11,692
Asian/Pacific Islander ^c	1,744	862	+	+	+	2,868	+	+	+
Males	1,083	554	+	+	+	1,796	+	+	+
Females	661	308	+	+	+	1,072	+	+	+
Hispanic ^d	6,595	3,247	+	+	+	11,131	+	+	+
Males	3,881	1,828	+	+	+	6,388	+	+	+
Females	2,714	1,419	+	+	+	4,743	+	+	+

Estimated prevalence percent^a on January 1, 2003, of the SEER 11 population diagnosed in the previous 10 years By Age at Prevalence, Race/Ethnicity and Sex

_	Age Specific (Crude)										
Age at Prevalence	All Ages	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70-79	80+	All Ages
Race/Sex											
All Races ^c	0.0450%	0.0072%	0.0043%	0.0018%	0.0075%	0.0304%	0.0830%	0.1660%	0.2164%	0.1811%	0.0478%
Males	0.0552%	0.0065%	0.0038%	0.0016%	0.0087%	0.0380%	0.1114%	0.2261%	0.3010%	0.2638%	0.0642%
Females	0.0351%	0.0080%	0.0048%	0.0020%	0.0062%	0.0230%	0.0562%	0.1124%	0.1527%	0.1362%	0.0346%
White ^c Males	0.0489% 0.0599%	0.0075% 0.0073%	0.0046% 0.0041%	0.0015% 0.0012%	0.0078% 0.0092%	0.0316% 0.0392%	0.0856% 0.1144%	0.1743% 0.2353%	0.2276% 0.3150%	0.1874% 0.2794%	0.0499% 0.0669%
Females	0.0380%	0.0078%	0.0052%	0.0019%	0.0063%	0.0239%	0.0576%	0.1184%	0.1606%	0.1380%	0.0359%
Black ^c Males Females	0.0406% 0.0475% 0.0343%	0.0081% 0.0055% 0.0108%	0.0052% 0.0045% 0.0060%	0.0037% 0.0035% 0.0038%	0.0093% 0.0096% 0.0090%	0.0366% 0.0459% 0.0285%	0.1023% 0.1377% 0.0729%	0.1831% 0.2550% 0.1268%	0.2175% 0.2951% 0.1665%	0.1939% 0.2391% 0.1725%	0.0535% 0.0696% 0.0417%
Asian/Pacific Islander' Males Females	0.0233% 0.0301% 0.0170%	0.0031% - 0.0048%	0.0010% 0.0016% -	0.0010% 0.0017% -	0.0037% 0.0046% 0.0029%	0.0160% 0.0218% 0.0108%	0.0449% 0.0632% 0.0290%	0.0846% 0.1204% 0.0548%	0.1273% 0.1889% 0.0827%	0.1014% 0.1339% 0.0795%	0.0258% 0.0363% 0.0176%
Hispanic ^d Males Females	0.0250% 0.0280% 0.0219%	0.0060% 0.0047% 0.0073%	0.0030% 0.0022% 0.0038%	0.0010% 0.0007% 0.0014%	0.0060% 0.0070% 0.0048%	0.0265% 0.0290% 0.0239%	0.0769% 0.1014% 0.0543%	0.1634% 0.2262% 0.1115%	0.2334% 0.2983% 0.1870%	0.1740% 0.2577% 0.1269%	0.0466% 0.0608% 0.0358%

US 2003 cancer prevalence counts are based on 2003 cancer prevalence proportions from the SEER registries and 1/1/2003 US population estimates based on the average of 2002 and 2003 population estimates from the US Bureau of the Census. Prevalence was calculated using the First Malignant Primary Only for a person.

Statistics based on (b) SEER 9 Areas (c) SEER 11 Areas and Rural Georgia (d) NHIA for Hispanic for SEER 11 Areas and Rural Georgia excluding Hawaii and Seattle.

Maximum limited-duration prevalence: 28 years for 1975-2003 SEER 9 data; 13 years for 1990-2003 SEER 11 data (used to calculate prevalence for Hispanics and Asian Pacific Islanders).

g h

Percentages are age-adjusted to the 2000 US standard population by 5-year age groups.

(g) Cases diagnosed more than 28 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000). (h)Complete prevalence is obtained by summing 0 to <28 and >=28.

Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

bcd

Table XII-16 LARYNX CANCER (Invasive)

Estimated United States Cancer Prevalence Counts^a on January 1, 2003 By Race/Ethnicity, Sex and Years Since Diagnosis

Years Since Diagnosis	0 to <5	5 to <10	10 to <15	15 to <20	20 to <25	0 to <13 ^e	0 to <28 ^e	>=28 ^g	Complete
Race/Sex									
All Races ^b	33,012	22,195	16,732	10,653	6,868	66,125	91,949	5,364	97,313
Males	26,366	17,843	13,270	8,701	5,489	52,896	73,689	4,382	78,071
Females	6,646	4,352	3,462	1,952	1,379	13,229	18,260	982	19,242
White ^b	27,539	19,213	14,541	9,405	6,300	56,249	79,234	4,378	83,612
Males	22,085	15,504	11,603	7,737	5,031	45,112	63,794	3,566	67,360
Females	5,454	3,709	2,938	1,668	1,269	11,137	15,440	812	16,252
Black ^b	4,569	2,541	1,879	1,072	470	8,322	10,756	370	11,126
Males	3,516	1,989	1,423	836	368	6,479	8,295	308	8,603
Females	1,053	552	456	236	102	1,843	2,461	62	2,523
Asian/Pacific Islander ^c	461	282	+	+	+	856	+	+	+
Males	395	246	+	+	+	740	+	+	+
Females	66	36	+	+	+	116	+	+	+
Hispanic ^d	1,466	783	+	+	+	2,673	+	+	+
Males	1,258	670	+	+	+	2,295	+	+	+
Females	208	113	+	+	+	378	+	+	+

Estimated prevalence percent^a on January 1, 2003, of the SEER 11 population diagnosed in the previous 10 years By Age at Prevalence, Race/Ethnicity and Sex

_	Age Specific (Crude)										Age-Adjustedf
Age at Prevalence	All Ages	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70-79	80+	All Ages
Race/Sex											
All Races ^c	0.0161%	_	_	0.0002%	0.0008%	0.0068%	0.0278%	0.0733%	0.0967%	0.0619%	0.0174%
Males	0.0262%	_	-	_	0.0010%	0.0099%	0.0471%	0.1253%	0.1821%	0.1416%	0.0316%
Females	0.0063%	-	-	0.0003%	0.0007%	0.0037%	0.0095%	0.0269%	0.0325%	0.0186%	0.0063%
White ^c	0.0173%	_	-	0.0002%	0.0010%	0.0068%	0.0281%	0.0753%	0.1006%	0.0625%	0.0179%
Males	0.0278%	_	_	_	0.0010%	0.0098%	0.0469%	0.1278%	0.1865%	0.1434%	0.0320%
Females	0.0068%	-	-	0.0003%	0.0009%	0.0037%	0.0097%	0.0272%	0.0348%	0.0192%	0.0065%
Black ^c	0.0182%	_	_	_	_	0.0113%	0.0478%	0.1158%	0.1167%	0.0819%	0.0253%
Males	0.0299%	-	-	_	-	0.0169%	0.0863%	0.2035%	0.2368%	0.1905%	0.0476%
Females	0.0076%	_	-	_	_	0.0064%	0.0159%	0.0471%	0.0379%	0.0302%	0.0096%
Asian/Pacific Islander	0.0070%	_	_	_	_	0.0026%	0.0089%	0.0273%	0.0563%	0.0400%	0.0081%
Males	0.0125%	-	-	_	-	0.0049%	0.0158%	0.0497%	0.1169%	0.0928%	0.0164%
Females	0.0018%	_	-	-	_	_	0.0028%	0.0087%	0.0125%	-	0.0019%
Hispanic ^d	0.0056%	_	_	_	0.0007%	0.0035%	0.0160%	0.0464%	0.0753%	0.0404%	0.0117%
Males	0.0094%	_	-	_	_	0.0054%	0.0288%	0.0885%	0.1604%	0.1027%	0.0236%
Females	0.0017%	-	-	-	0.0008%	0.0017%	0.0041%	0.0116%	0.0144%	-	0.0028%

US 2003 cancer prevalence counts are based on 2003 cancer prevalence proportions from the SEER registries and 1/1/2003 US population estimates based on the average of 2002 and 2003 population estimates from the US Bureau of the Census. Prevalence was calculated using the First Malignant Primary Only for a person.

Statistics based on (b) SEER 9 Areas (c) SEER 11 Areas and Rural Georgia (d) NHIA for Hispanic for SEER 11 Areas and Rural Georgia excluding Hawaii and Seattle.

Maximum limited-duration prevalence: 28 years for 1975-2003 SEER 9 data; 13 years for 1990-2003 SEER 11 data (used to calculate prevalence for Hispanics and Asian Pacific Islanders).

g h

Percentages are age-adjusted to the 2000 US standard population by 5-year age groups.

(g) Cases diagnosed more than 28 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000). (h)Complete prevalence is obtained by summing 0 to <28 and >=28.

Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

bcd

Table XIII-24 LEUKEMIA (Invasive)

Estimated United States Cancer Prevalence Counts^a on January 1, 2003 By Race/Ethnicity, Sex and Years Since Diagnosis

Years Since Diagnosis	0 to <5	5 to <10	10 to <15	15 to <20	20 to <25	0 to <13 ^e	0 to <28 ^e	>=28 ^g	<u>Complete</u> h
<u>Race/Sex</u> All Races ^b Males Females	82,812 48,279 34,533	49,232 27,762 21,470	28,886 16,288 12,598	17,622 9,832 7,790	10,054 5,224 4,830	150,896 86,589 64,307	192,632 109,292 83,340	6,381 3,032 3,349	199,013 112,324 86,689
White ^b	73,757	44,001	26,200	16,091	9,134	134,884	172,889	5,415	178,304
Males	43,299	24,794	14,980	9,043	4,758	77,821	98,693	2,223	100,916
Females	30,458	19,207	11,220	7,048	4,376	57,063	74,196	3,192	77,388
Black ^b	5,061	3,047	1,528	883	541	9,126	11,299	616	11,915
Males	2,549	1,594	708	445	264	4,593	5,638	295	5,933
Females	2,512	1,453	820	438	277	4,533	5,661	321	5,982
Asian/Pacific Islander ^c	1,747	970	+	+	+	3,159	+	+	+
Males	987	538	+	+	+	1,764	+	+	+
Females	760	432	+	+	+	1,395	+	+	+
Hispanic ^d	6,505	3,779	+	+	+	11,989	+	+	+
Males	3,546	2,191	+	+	+	6,773	+	+	+
Females	2,959	1,588	+	+	+	5,216	+	+	+

Estimated prevalence percent on January 1, 2003, of the SEER 11 population diagnosed in the previous 10 years By Age at Prevalence, Race/Ethnicity and Sex

	Age Specific (Crude)										
Age at Prevalence	All Ages	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70-79	+08	All Ages
Race/Sex											
All Races ^c	0.0413%	0.0284%	0.0303%	0.0131%	0.0143%	0.0240%	0.0474%	0.1029%	0.1515%	0.1650%	0.0432%
Males	0.0482%	0.0299%	0.0327%	0.0143%	0.0171%	0.0293%	0.0613%	0.1359%	0.2062%	0.2210%	0.0543%
Females	0.0345%	0.0268%	0.0277%	0.0118%	0.0113%	0.0187%	0.0343%	0.0735%	0.1103%	0.1345%	0.0341%
White ^c	0.0465%	0.0318%	0.0339%	0.0144%	0.0149%	0.0255%	0.0511%	0.1139%	0.1673%	0.1794%	0.0473%
Males	0.0541%	0.0333%	0.0365%	0.0158%	0.0176%	0.0307%	0.0663%	0.1500%	0.2271%	0.2433%	0.0594%
Females	0.0389%	0.0302%	0.0311%	0.0128%	0.0120%	0.0201%	0.0363%	0.0808%	0.1215%	0.1451%	0.0373%
Black ^c	0.0214%	0.0106%	0.0164%	0.0081%	0.0110%	0.0161%	0.0328%	0.0635%	0.0923%	0.0918%	0.0259%
Males	0.0239%	0.0104%	0.0175%	0.0078%	0.0141%	0.0212%	0.0407%	0.0776%	0.1195%	0.1013%	0.0311%
Females	0.0191%	0.0108%	0.0154%	0.0083%	0.0082%	0.0117%	0.0262%	0.0524%	0.0744%	0.0873%	0.0220%
Asian/Pacific Islander	° 0.0217%	0.0270%	0.0230%	0.0104%	0.0128%	0.0168%	0.0237%	0.0392%	0.0446%	0.0474%	0.0228%
Males	0.0252%	0.0301%	0.0266%	0.0109%	0.0155%	0.0212%	0.0250%	0.0457%	0.0587%	0.0723%	0.0272%
Females	0.0184%	0.0238%	0.0193%	0.0099%	0.0103%	0.0128%	0.0225%	0.0338%	0.0345%	0.0306%	0.0191%
Hispanic ^d	0.0267%	0.0314%	0.0358%	0.0137%	0.0143%	0.0195%	0.0329%	0.0542%	0.0672%	0.0672%	0.0306%
Males	0.0288%	0.0326%	0.0393%	0.0155%	0.0169%	0.0196%	0.0362%	0.0629%	0.0948%	0.0841%	0.0352%
Females	0.0244%	0.0302%	0.0321%	0.0115%	0.0114%	0.0194%	0.0298%	0.0470%	0.0475%	0.0578%	0.0267%

US 2003 cancer prevalence counts are based on 2003 cancer prevalence proportions from the SEER registries and 1/1/2003 US population estimates based on the average of 2002 and 2003 population estimates from the US Bureau of the Census. Prevalence was calculated using the First Malignant Primary Only for a person.

Statistics based on (b) SEER 9 Areas (c) SEER 11 Areas and Rural Georgia (d) NHIA for Hispanic for SEER 11 Areas and Rural Georgia excluding Hawaii and Seattle.

Maximum limited-duration prevalence: 28 years for 1975-2003 SEER 9 data; 13 years for 1990-2003 SEER 11 data (used to calculate prevalence for Hispanics and Asian Pacific Islanders).

g h

bcd

Percentages are age-adjusted to the 2000 US standard population by 5-year age groups.

(g) Cases diagnosed more than 28 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000). (h)Complete prevalence is obtained by summing 0 to <28 and >=28.

Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

Table XIII-25 ACUTE LYMPHOCYTIC LEUKEMIA (Invasive)

Estimated United States Cancer Prevalence Counts^a on January 1, 2003 By Race/Ethnicity, Sex and Years Since Diagnosis

Years Since Diagnosis	0 to <5	5 to <10	10 to <15	15 to <20	20 to <25	0 to <13 ^e	0 to <28 ^e	>=28 ^g	Complete
Da = 2 / Gas-									
<u>Race/Sex</u> All Races ^b	13,967	10,519	8,957	6,868	5,165	29,995	47,535	3,404	50,939
Males	7,952	5,845	5,007	3,758	2,605	16,864	26,215	1,863	28,078
Females	6,015	4,674	3,950	3,110	2,560	13,131	21,320	1,541	22,861
White ^b	12,273	9,080	7,889	6,081	4,685	26,186	41,927	+	+
Males	7,020	5,041	4,503	3,365	2,381	14,839	23,321	+	+
Females	5,253	4,039	3,386	2,716	2,304	11,347	18,606	+	+
Black ^b	839	751	590	414	244	1,981	2,928	+	+
Males	443	408	280	212	108	1,013	1,482	+	+
Females	396	343	310	202	136	968	1,446	+	+
Asian/Pacific Islander ^c	555	392	+	+	+	1,172	+	+	+
Males	323	229	+	+	+	659	+	+	+
Females	232	163	+	+	+	513	+	+	+
Hispanic ^d	3,156	2,172	+	+	+	6,276	+	+	+
Males	1,716	1,299	+	+	+	3,577	+	+	+
Females	1,440	873	+	+	+	2,699	+	+	+

Estimated prevalence percent^a on January 1, 2003, of the SEER 11 population diagnosed in the previous 10 years By Age at Prevalence, Race/Ethnicity and Sex

	Age Specific (Crude)										Age-Adjustedf
Age at Prevalence	All Ages	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70-79	80+	All Ages
Race/Sex											
All Races ^c	0.0092%	0.0247%	0.0254%	0.0063%	0.0028%	0.0018%	0.0022%	0.0021%	0.0011%	0.0008%	0.0092%
Males	0.0105%	0.0259%	0.0278%	0.0079%	0.0037%	0.0017%	0.0026%	0.0027%	0.0013%	-	0.0102%
Females	0.0080%	0.0234%	0.0228%	0.0046%	0.0019%	0.0020%	0.0019%	0.0016%	0.0010%	0.0009%	0.0082%
White ^c	0.0102%	0.0279%	0.0289%	0.0074%	0.0031%	0.0021%	0.0024%	0.0023%	0.0013%	0.0007%	0.0105%
Males	0.0115%	0.0290%	0.0316%	0.0090%	0.0041%	0.0019%	0.0028%	0.0031%	0.0016%	-	0.0115%
Females	0.0089%	0.0268%	0.0260%	0.0056%	0.0019%	0.0022%	0.0020%	0.0015%	0.0010%	0.0009%	0.0094%
Black ^c	0.0042%	0.0084%	0.0119%	0.0026%	0.0008%	0.0007%	-	-	-	-	0.0037%
Males	0.0047%	0.0081%	0.0127%	0.0035%	-	-	-	-	-	-	0.0039%
Females	0.0038%	0.0087%	0.0112%	0.0018%	-	-	-	-	-	-	0.0034%
Asian/Pacific Islander	0.0070%	0.0220%	0.0185%	0.0034%	0.0029%	0.0013%	0.0019%	0.0022%	-	-	0.0074%
Males	0.0084%	0.0256%	0.0215%	0.0046%	0.0034%	-	0.0020%	-	-	-	0.0085%
Females	0.0056%	0.0182%	0.0153%	0.0023%	0.0024%	0.0015%	0.0018%	0.0029%	-	-	0.0062%
Hispanic ^d	0.0139%	0.0281%	0.0306%	0.0076%	0.0037%	0.0034%	0.0038%	0.0022%	-	-	0.0113%
Males	0.0153%	0.0290%	0.0347%	0.0090%	0.0048%	0.0032%	0.0037%	-	-	-	0.0123%
Females	0.0125%	0.0273%	0.0263%	0.0060%	0.0025%	0.0035%	0.0040%	-	-	-	0.0101%

US 2003 cancer prevalence counts are based on 2003 cancer prevalence proportions from the SEER registries and 1/1/2003 US population estimates based on the average of 2002 and 2003 population estimates from the US Bureau of the Census. Prevalence was calculated using the First Malignant Primary Only for a person.

Statistics based on (b) SEER 9 Areas (c) SEER 11 Areas and Rural Georgia (d) NHIA for Hispanic for SEER 11 Areas and Rural Georgia excluding Hawaii and Seattle.

Maximum limited-duration prevalence: 28 years for 1975-2003 SEER 9 data; 13 years for 1990-2003 SEER 11 data (used to calculate prevalence for Hispanics and Asian Pacific Islanders).

g h

Percentages are age-adjusted to the 2000 US standard population by 5-year age groups.

(g) Cases diagnosed more than 28 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000). (h)Complete prevalence is obtained by summing 0 to <28 and >=28.

Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

bcd

Table XIV-16 LIVER AND INTRAHEPATIC BILE DUCT CANCER (Invasive)

Estimated United States Cancer Prevalence Counts^a on January 1, 2003 By Race/Ethnicity, Sex and Years Since Diagnosis

Years Since Diagnosis	0 to <5	5 to <10	10 to <15	15 to <20	20 to <25	0 to <13 ^e	0 to <28 ^e	>=28 ^g	Completeh
Race/Sex									
All Races ^b	12,879	2,073	922	768	271	15,647	16,970	375	17,345
Males	8,577	1,248	484	304	133	10,212	10,783	67	10,850
Females	4,302	825	438	464	138	5,435	6,187	308	6,495
White ^b	9,456	1,582	759	622	203	11,610	12,655	316	12,971
Males	6,235	926	378	228	93	7,470	7,893	97 ⁱ	7,990
Females	3,221	656	381	394	110	4,140	4,762	219 ⁱ	4,981
Black ^b	1,451	146	87	86	46	1,659	1,828	+	+
Males	983	97	51	39	35	1,118	1,205	+	+
Females	468	49	36	47	11	541	623	+	+
Asian/Pacific Islander ^c	1,690	270	+	+	+	2,026	+	+	+
Males	1,143	186	+	+	+	1,370	+	+	+
Females	547	84	+	+	+	656	+	+	+
Hispanic ^d	1,803	266	+	+	+	2,146	+	+	+
Males	1,190	157	+	+	+	1,411	+	+	+
Females	613	109	+	+	+	735	+	+	+

Estimated prevalence percent on January 1, 2003, of the SEER 11 population diagnosed in the previous 10 years By Age at Prevalence, Race/Ethnicity and Sex

_	Age Specific (Crude)										Age-Adjustedf
Age at Prevalence	All Ages	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70-79	+08	All Ages
Race/Sex											
All Races ^c	0.0064%	0.0017%	0.0004%	0.0004%	0.0009%	0.0043%	0.0136%	0.0240%	0.0284%	0.0194%	0.0068%
Males	0.0086%	0.0016%	0.0005%	0.0004%	0.0011%	0.0062%	0.0217%	0.0334%	0.0429%	0.0271%	0.0097%
Females	0.0043%	0.0018%	0.0003%	0.0005%	0.0007%	0.0025%	0.0060%	0.0157%	0.0176%	0.0152%	0.0042%
White ^c	0.0050%	0.0016%	0.0004%	0.0003%	0.0007%	0.0035%	0.0109%	0.0169%	0.0189%	0.0152%	0.0050%
Males	0.0066%	0.0013%	0.0006%	0.0003%	0.0007%	0.0048%	0.0177%	0.0230%	0.0280%	0.0208%	0.0071%
Females	0.0034%	0.0018%	-	0.0004%	0.0007%	0.0022%	0.0043%	0.0114%	0.0120%	0.0122%	0.0032%
Black ^c	0.0041%	0.0007%	-	-	0.0011%	0.0024%	0.0141%	0.0184%	0.0229%	0.0060%	0.0052%
Males	0.0058%	-	-	-	0.0015%	0.0039%	0.0211%	0.0301%	0.0403%	-	0.0083%
Females	0.0025%	-	-	-	-	-	0.0082%	0.0092%	0.0115%	-	0.0029%
Asian/Pacific Islander	0.0175%	0.0031%	-	0.0009%	0.0020%	0.0114%	0.0308%	0.0741%	0.0966%	0.0667%	0.0194%
Males	0.0243%	0.0029%	-	-	0.0036%	0.0181%	0.0491%	0.1086%	0.1481%	0.0852%	0.0289%
Females	0.0112%	0.0033%	-	-	-	0.0053%	0.0146%	0.0454%	0.0593%	0.0542%	0.0117%
Hispanic ^d	0.0052%	0.0015%	0.0004%	0.0004%	0.0006%	0.0053%	0.0180%	0.0396%	0.0386%	0.0373%	0.0097%
Males	0.0066%	0.0014%	0.0007%	-	0.0007%	0.0082%	0.0286%	0.0521%	0.0579%	0.0399%	0.0135%
Females	0.0038%	0.0017%	-	-	-	0.0023%	0.0082%	0.0293%	0.0248%	0.0359%	0.0065%

bcd

US 2003 cancer prevalence counts are based on 2003 cancer prevalence proportions from the SEER registries and 1/1/2003 US population estimates based on the average of 2002 and 2003 population estimates from the US Bureau of the Census. Prevalence was calculated using the First Malignant Primary Only for a person.

Statistics based on (b) SEER 9 Areas (c) SEER 11 Areas and Rural Georgia (d) NHIA for Hispanic for SEER 11 Areas and Rural Georgia excluding Hawaii and Seattle.

Maximum limited-duration prevalence: 28 years for 1975-2003 SEER 9 data; 13 years for 1990-2003 SEER 11 data (used to calculate prevalence for Hispanics and Asian Pacific Islanders).

Percentages are age-adjusted to the 2000 US standard population by 5-year age groups.

(g) Cases diagnosed more than 28 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000). (h)Complete prevalence is obtained by summing 0 to <28 and >=28. (i)Age-specific completeness index was approximated using empirical data from historical Connecticut tumor registry.

Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

f

Table XV-22 LUNG AND BRONCHUS CANCER (Invasive)

Estimated United States Cancer Prevalence Counts^a on January 1, 2003 By Race/Ethnicity, Sex and Years Since Diagnosis

Years Since Diagnosis	0 to <5	5 to <10	10 to <15	15 to <20	20 to <25	0 to <13 ^e	0 to <28 ^e	>=28 ^g	Complete
Race/Sex									
All Races ^b	204,290	67,858	35,894	19,317	9,930	296,216	340,934	14,055	354,989
Males	99,565	32,212	17,329	9,309	5,053	143,137	165,339	8,092	173,431
Females	104,725	35,646	18,565	10,008	4,877	153,079	175,595	5,963	181,558
White ^b	176,378	59,458	32,082	17,097	8,800	257,369	297,029	7,069	304,098
Males	85,040	27,731	15,357	8,040	4,455	122,849	142,233	3,533	145,766
Females	91,338	31,727	16,725	9,057	4,345	134,520	154,796	3,536	158,332
Black ^b	21,525	6,543	2,972	1,806	878	30,036	34,061	710	34,771
Males	11,024	3,393	1,510	996	478	15,396	17,628	388	18,016
Females	10,501	3,150	1,462	810	400	14,640	16,433	322	16,755
Asian/Pacific Islander ^c	4,533	1,224	+	+	+	6,166	+	+	+
Males	2,519	712	+	+	+	3,468	+	+	+
Females	2,014	512	+	+	+	2,698	+	+	+
Hispanic ^d	5,392	1,470	+	+	+	7,525	+	+	+
Males	2,886	733	+	+	+	3,906	+	+	+
Females	2,506	737	+	+	+	3,619	+	+	+

Estimated prevalence percent on January 1, 2003, of the SEER 11 population diagnosed in the previous 10 years By Age at Prevalence, Race/Ethnicity and Sex

_	Age Specific (Crude)										Age-Adjustedf
Age at Prevalence	All Ages	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70-79	80+	All Ages
Race/Sex											
All Races ^c	0.0789%	-	0.0002%	0.0012%	0.0042%	0.0240%	0.1092%	0.3342%	0.5510%	0.3785%	0.0863%
Males	0.0781%	_	0.0003%	0.0010%	0.0038%	0.0228%	0.1110%	0.3612%	0.6360%	0.4728%	0.0962%
Females	0.0797%	_	_	0.0014%	0.0046%	0.0252%	0.1076%	0.3102%	0.4870%	0.3273%	0.0792%
White ^c	0.0849%	_	0.0002%	0.0013%	0.0043%	0.0232%	0.1086%	0.3461%	0.5732%	0.3808%	0.0884%
Males	0.0813%	_	0.0003%	0.0010%	0.0039%	0.0211%	0.1055%	0.3602%	0.6439%	0.4637%	0.0954%
Females	0.0885%	-	-	0.0017%	0.0047%	0.0254%	0.1116%	0.3332%	0.5190%	0.3364%	0.0836%
Black ^c	0.0686%	_	_	0.0009%	0.0044%	0.0378%	0.1619%	0.4028%	0.5462%	0.3367%	0.0980%
Males	0.0758%	_	_	_	0.0039%	0.0423%	0.1996%	0.5019%	0.6733%	0.4973%	0.1227%
Females	0.0621%	_	-	_	0.0049%	0.0339%	0.1307%	0.3251%	0.4626%	0.2603%	0.0808%
Asian/Pacific Islander	0.0543%	_	_	_	0.0036%	0.0172%	0.0724%	0.2115%	0.3991%	0.3733%	0.0627%
Males	0.0631%	_	_	_	0.0028%	0.0183%	0.0804%	0.2692%	0.5562%	0.5155%	0.0820%
Females	0.0461%	_	_	_	0.0043%	0.0162%	0.0654%	0.1633%	0.2853%	0.2774%	0.0484%
Hispanic ^d	0.0173%	_	_	0.0009%	0.0020%	0.0111%	0.0372%	0.1323%	0.2484%	0.1980%	0.0374%
Males	0.0175%	_	_	0.0009%	0.0018%	0.0099%	0.0421%	0.1459%	0.3292%	0.2681%	0.0459%
Females	0.0171%	=	_	0.0009%	0.0022%	0.0123%	0.0327%	0.1212%	0.1908%	0.1586%	0.0316%

US 2003 cancer prevalence counts are based on 2003 cancer prevalence proportions from the SEER registries and 1/1/2003 US population estimates based on the average of 2002 and 2003 population estimates from the US Bureau of the Census. Prevalence was calculated using the First Malignant Primary Only for a person.

Statistics based on (b) SEER 9 Areas (c) SEER 11 Areas and Rural Georgia (d) NHIA for Hispanic for SEER 11 Areas and Rural Georgia excluding Hawaii and Seattle.

Maximum limited-duration prevalence: 28 years for 1975-2003 SEER 9 data; 13 years for 1990-2003 SEER 11 data (used to calculate prevalence for Hispanics and Asian Pacific Islanders).

Percentages are age-adjusted to the 2000 US standard population by 5-year age groups.

(g) Cases diagnosed more than 28 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000). (h)Complete prevalence is obtained by summing 0 to <28 and >=28.

Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

bcd

g h

⁺ Not available.

Table XVI-16 MELANOMA OF THE SKIN (Invasive)

Estimated United States Cancer Prevalence Counts^a on January 1, 2003 By Race/Ethnicity, Sex and Years Since Diagnosis

Years Since Diagnosis	0 to <5	5 to <10	10 to <15	15 to <20	20 to <25	0 to <13 ^e	0 to <28 ^e	>=28 ^g	Complete ^h
Race/Sex									
All Races ^b	210,287	148,009	105,637	77,558	51,695	426,216	612,953	49,480	662,433
Males	111,633	75,690	51,441	34,790	21,189	221,141	303,073	17,105	320,178
Females	98,654	72,319	54,196	42,768	30,506	205,075	309,880	32,375	342,255
White ^b	202,508	141,196	101,167	73,290	50,207	408,761	586,926	46,714	633,640
Males	107,569	72,263	49,546	32,957	20,553	212,326	290,664	16,278	306,942
Females	94,939	68,933	51,621	40,333	29,654	196,435	296,262	30,436	326,698
Black ^b	865	553	433	181	113	1,644	2,259	145	2,404
Males	408	298	176	24	36	813	969	57	1,026
Females	457	255	257	157	77	831	1,290	88	1,378
Asian/Pacific Islander ^c	512	309	+	+	+	921	+	+	+
Males	219	169	+	+	+	413	+	+	+
Females	293	140	+	+	+	508	+	+	+
Hispanic ^d	3,460	2,190	+	+	+	6,693	+	+	+
Males	1,348	822	+	+	+	2,553	+	+	+
Females	2,112	1,368	+	+	+	4,140	+	+	+

Estimated prevalence percent^a on January 1, 2003, of the SEER 11 population diagnosed in the previous 10 years By Age at Prevalence, Race/Ethnicity and Sex

_	Age Specific (Crude)										Age-Adjustedf
Age at Prevalence	All Ages	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70-79	+08	All Ages
Race/Sex											
All Races ^c	0.1040%	0.0003%	0.0026%	0.0246%	0.0693%	0.1340%	0.2022%	0.2709%	0.3406%	0.3144%	0.1076%
Males	0.1109%	0.0002%	0.0020%	0.0163%	0.0506%	0.1233%	0.2269%	0.3535%	0.4893%	0.4942%	0.1256%
Females	0.0973%	0.0003%	0.0033%	0.0332%	0.0885%	0.1446%	0.1787%	0.1973%	0.2287%	0.2167%	0.0955%
White ^c	0.1290%	0.0003%	0.0032%	0.0307%	0.0862%	0.1644%	0.2441%	0.3261%	0.4011%	0.3556%	0.1294%
Males	0.1364%	0.0003%	0.0022%	0.0196%	0.0611%	0.1492%	0.2706%	0.4195%	0.5706%	0.5679%	0.1486%
Females	0.1215%	0.0003%	0.0041%	0.0428%	0.1130%	0.1799%	0.2184%	0.2406%	0.2711%	0.2418%	0.1169%
Black ^c	0.0038%	_	_	_	0.0029%	0.0031%	0.0076%	0.0169%	0.0190%	0.0209%	0.0050%
Males	0.0038%	_	_	_	0.0020%	0.0032%	0.0083%	0.0215%	0.0256%	0.0256%	0.0059%
Females	0.0038%	_	_	_	0.0037%	0.0031%	0.0069%	0.0132%	0.0146%	0.0187%	0.0044%
Asian/Pacific Islander	0.0070%	_	=	0.0017%	0.0062%	0.0062%	0.0131%	0.0171%	0.0243%	0.0302%	0.0074%
Males	0.0070%	_	_	0.0017%	0.0036%	0.0046%	0.0137%	0.0211%	0.0398%	0.0317%	0.0083%
Females	0.0070%	-	-	0.0017%	0.0087%	0.0076%	0.0127%	0.0139%	0.0131%	0.0292%	0.0069%
Hispanic ^d	0.0146%	_	_	0.0033%	0.0128%	0.0264%	0.0462%	0.0525%	0.0943%	0.0964%	0.0244%
Males	0.0107%	_	_	0.0015%	0.0058%	0.0177%	0.0345%	0.0525%	0.1151%	0.1349%	0.0229%
Females	0.0187%	_	-	0.0055%	0.0208%	0.0354%	0.0570%	0.0525%	0.0794%	0.0747%	0.0269%

US 2003 cancer prevalence counts are based on 2003 cancer prevalence proportions from the SEER registries and 1/1/2003 US population estimates based on the average of 2002 and 2003 population estimates from the US Bureau of the Census. Prevalence was calculated using the First Malignant Primary Only for a person.

Statistics based on (b) SEER 9 Areas (c) SEER 11 Areas and Rural Georgia (d) NHIA for Hispanic for SEER 11 Areas and Rural Georgia excluding Hawaii and Seattle.

Maximum limited-duration prevalence: 28 years for 1975-2003 SEER 9 data; 13 years for 1990-2003 SEER 11 data (used to calculate prevalence for Hispanics and Asian Pacific Islanders).

g h

Percentages are age-adjusted to the 2000 US standard population by 5-year age groups.

(g) Cases diagnosed more than 28 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000). (h)Complete prevalence is obtained by summing 0 to <28 and >=28.

Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

bcd

Table XVII-11 MESOTHELIOMA (Invasive)

Estimated United States Cancer Prevalence Counts^a on January 1, 2003 By Race/Ethnicity, Sex and Years Since Diagnosis

Years Since Diagnosis	0 to <5	5 to <10	10 to <15	15 to <20	20 to <25	0 to <13 ^e	0 to <28 ^e	>=28 ^g	Complete ^h
Race/Sex									
All Races ^b	2,802	598	315	192	151	3,619	4,182	+	+
Males	1,903	269	87	96	72	2,232	2,438	+	+
Females	899	329	228	96	79	1,387	1,744	+	+
White ^b	2,609	523	279	167	138	3,319	3,828	+	+
Males	1,770	233	70	71	59	2,051	2,214	+	+
Females	839	290	209	96	79	1,268	1,614	+	+
Black ^b	116	61	26	22	13	202	249	+	+
Males	81	36	13	22	13	130	165	+	+
Females	35	25	13	0	0	72	84	+	+
Asian/Pacific Islander ^c	19	9	+	+	+	32	+	+	+
Males	14	7	+	+	+	21	+	+	+
Females	5	2	+	+	+	11	+	+	+
Hispanic ^d	213	20	+	+	+	243	+	+	+
Males	167	10	+	+	+	177	+	+	+
Females	46	10	+	+	+	66	+	+	+

Estimated prevalence percent on January 1, 2003, of the SEER 11 population diagnosed in the previous 10 years By Age at Prevalence, Race/Ethnicity and Sex

_	Age Specific (Crude)										
Age at Prevalence	All Ages	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70-79	80+	All Ages
Race/Sex											
All Races ^c	0.0010%	-	-	-	0.0001%	0.0006%	0.0017%	0.0036%	0.0050%	0.0063%	0.0011%
Males	0.0014%	-	-	-	-	0.0007%	0.0018%	0.0050%	0.0098%	0.0127%	0.0017%
Females	0.0007%	=	=	=	0.0002%	0.0006%	0.0015%	0.0023%	0.0014%	0.0028%	0.0007%
White ^c	0.0012%	-	_	-	0.0002%	0.0007%	0.0018%	0.0041%	0.0059%	0.0068%	0.0012%
Males	0.0016%	-		-	-	0.0007%	0.0020%	0.0058%	0.0113%	0.0136%	0.0019%
Females	0.0008%	=	=	=	0.0003%	0.0007%	0.0017%	0.0026%	0.0017%	0.0031%	0.0008%
Black ^c	0.0005%	-	-	-	-	-	0.0011%	0.0021%	-	-	0.0006%
Males	0.0007%	-	-	-	-	-	-	-	_	_	0.0012%
Females	0.0003%	-	-	-	_	-	-	-	-	-	0.0003%
Asian/Pacific Islander	° 0.0003%	_	_	_	_	_	_	_	_	_	0.0003%
Males	0.0004%	_	-	_	-	_	_	_	_	_	0.0005%
Females	-	-	-	-	_	-	-	-	-	-	-
Hispanic ^d	0.0006%	-	_	-	_	0.0008%	0.0016%	0.0034%	0.0067%	0.0077%	0.0012%
Males	0.0009%	-	-	-	-	-	0.0025%	0.0060%	0.0135%	-	0.0022%
Females	0.0003%	-	-	-	-	-	-	_	_	-	0.0005%

bcd

US 2003 cancer prevalence counts are based on 2003 cancer prevalence proportions from the SEER registries and 1/1/2003 US population estimates based on the average of 2002 and 2003 population estimates from the US Bureau of the Census. Prevalence was calculated using the First Malignant Primary Only for a person.

Statistics based on (b) SEER 9 Areas (c) SEER 11 Areas and Rural Georgia (d) NHIA for Hispanic for SEER 11 Areas and Rural Georgia excluding Hawaii and Seattle.

Maximum limited-duration prevalence: 28 years for 1975-2003 SEER 9 data; 13 years for 1990-2003 SEER 11 data (used to calculate prevalence for Hispanics and Asian Pacific Islanders).

Percentages are age-adjusted to the 2000 US standard population by 5-year age groups.

(g) Cases diagnosed more than 28 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000). (h)Complete prevalence is obtained by summing 0 to <28 and >=28. (i)Age-specific completeness index was approximated using empirical data from historical Connecticut tumor registry.

Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

f

Table XVIII-16 MYELOMA (Invasive)

Estimated United States Cancer Prevalence Counts^a on January 1, 2003 By Race/Ethnicity, Sex and Years Since Diagnosis

Years Since Diagnosis	0 to <5	5 to <10	10 to <15	15 to <20	20 to <25	0 to <13 ^e	0 to <28 ^e	>=28 ^g	Completeh
rears since Diagnosis	0 00 03	3 60 <10	10 00 <13	13 (0 \20	20 00 025	0 00 113	0 00 020	/-20	Complete
Race/Sex									
All Races ^b	35,577	10,419	3,613	1,398	436	48,763	51,578	352	51,930
Males	19,965	5,694	1,973	829	169	27,179	28,677	141	28,818
Females	15,612	4,725	1,640	569	267	21,584	22,901	211	23,112
White ^b	28,132	8,200	2,665	1,015	329	38,430	40,450	67	40,517
Males	16,304	4,620	1,528	574	126	22,128	23,199	0 ⁱ	23,199
Females	11,828	3,580	1,137	441	203	16,302	17,251	67 ⁱ	17,318
Black ^b	6,203	1,848	829	332	91	8,633	9,329	+	+
Males	3,012	857	402	222	40	4,148	4,533	+	+
Females	3,191	991	427	110	51	4,485	4,796	+	+
Asian/Pacific Islander ^c	684	208	+	+	+	937	+	+	+
Males	351	128	+	+	+	498	+	+	+
Females	333	80	+	+	+	439	+	+	+
Hispanic ^d	2,104	573	+	+	+	2,837	+	+	+
Males	1,093	327	+	+	+	1,522	+	+	+
Females	1,011	246	+	+	+	1,315	+	+	+

Estimated prevalence percent on January 1, 2003, of the SEER 11 population diagnosed in the previous 10 years By Age at Prevalence, Race/Ethnicity and Sex

_	Age Specific (Crude)										Age-Adjustedf
Age at Prevalence	All Ages	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70-79	80+	All Ages
Race/Sex											
All Races ^c	0.0141%	-	_	0.0002%	0.0016%	0.0069%	0.0252%	0.0531%	0.0816%	0.0711%	0.0152%
Males	0.0158%	-	_	0.0002%	0.0023%	0.0085%	0.0303%	0.0654%	0.1045%	0.0845%	0.0188%
Females	0.0125%	-	-	-	0.0010%	0.0052%	0.0203%	0.0421%	0.0645%	0.0639%	0.0122%
White ^c	0.0140%	_	_	0.0001%	0.0016%	0.0065%	0.0235%	0.0502%	0.0775%	0.0663%	0.0143%
Males	0.0159%	-	-	-	0.0022%	0.0080%	0.0296%	0.0631%	0.1004%	0.0814%	0.0181%
Females	0.0120%	_	=	=	0.0009%	0.0049%	0.0175%	0.0385%	0.0600%	0.0582%	0.0112%
Black ^c	0.0204%	_	_	_	0.0031%	0.0124%	0.0475%	0.1025%	0.1620%	0.1333%	0.0293%
Males	0.0209%	_	_	_	0.0041%	0.0153%	0.0486%	0.1250%	0.2054%	0.1213%	0.0338%
Females	0.0200%	-	=	=	0.0023%	0.0098%	0.0466%	0.0848%	0.1335%	0.1391%	0.0259%
Asian/Pacific Islander	0.0083%	_	=	_	_	0.0042%	0.0159%	0.0277%	0.0490%	0.0578%	0.0094%
Males	0.0091%	_	_	_	_	0.0054%	0.0183%	0.0291%	0.0627%	0.0747%	0.0114%
Females	0.0075%	-	_	_	_	0.0032%	0.0138%	0.0265%	0.0391%	0.0463%	0.0078%
Hispanic ^d	0.0068%	_	_	_	0.0018%	0.0063%	0.0204%	0.0446%	0.0808%	0.0633%	0.0138%
Males	0.0070%	_	_	_	0.0027%	0.0068%	0.0237%	0.0425%	0.0998%	0.0988%	0.0165%
Females	0.0066%	-	_	_	_	0.0058%	0.0174%	0.0463%	0.0673%	0.0433%	0.0119%

bcd

US 2003 cancer prevalence counts are based on 2003 cancer prevalence proportions from the SEER registries and 1/1/2003 US population estimates based on the average of 2002 and 2003 population estimates from the US Bureau of the Census. Prevalence was calculated using the First Malignant Primary Only for a person.

Statistics based on (b) SEER 9 Areas (c) SEER 11 Areas and Rural Georgia (d) NHIA for Hispanic for SEER 11 Areas and Rural Georgia excluding Hawaii and Seattle.

Maximum limited-duration prevalence: 28 years for 1975-2003 SEER 9 data; 13 years for 1990-2003 SEER 11 data (used to calculate prevalence for Hispanics and Asian Pacific Islanders).

Percentages are age-adjusted to the 2000 US standard population by 5-year age groups.

(g) Cases diagnosed more than 28 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000). (h)Complete prevalence is obtained by summing 0 to <28 and >=28. (i)Age-specific completeness index was approximated using empirical data from historical Connecticut tumor registry.

Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

f

Table XIX-20 NON-HODGKIN LYMPHOMA (Invasive)

Estimated United States Cancer Prevalence Counts^a on January 1, 2003 By Race/Ethnicity, Sex and Years Since Diagnosis

Years Since Diagnosis	0 to <5	5 to <10	10 to <15	15 to <20	20 to <25	0 to <13 ^e	0 to <28 ^e	>=28 ^g	Complete
Race/Sex									
All Races ^b	159,781	90,954	49,972	29,129	15,558	283,945	350,868	13,617	364,485
Males	83,817	47,332	25,739	15,059	7,956	148,234	182,423	7,214	189,637
Females	75,964	43,622	24,233	14,070	7,602	135,711	168,445	6,403	174,848
White ^b	142,460	80,931	45,275	26,644	14,245	253,405	314,595	13,744	328,339
Males	74,940	41,785	23,320	13,762	7,290	132,119	163,496	7,685	171,181
Females	67,520	39,146	21,955	12,882	6,955	121,286	151,099	6,059	157,158
Black ^b	10,915	6,245	3,139	1,604	949	19,314	23,165	985	24,150
Males	5,497	3,521	1,613	849	466	10,150	12,018	448	12,466
Females	5,418	2,724	1,526	755	483	9,164	11,147	537	11,684
Asian/Pacific Islander ^c	3,608	1,987	+	+	+	6,244	+	+	+
Males	1,898	985	+	+	+	3,222	+	+	+
Females	1,710	1,002	+	+	+	3,022	+	+	+
Hispanic ^d	8,981	4,524	+	+	+	15,073	+	+	+
Males	4,837	2,377	+	+	+	8,001	+	+	+
Females	4,144	2,147	+	+	+	7,072	+	+	+

Estimated prevalence percent^a on January 1, 2003, of the SEER 11 population diagnosed in the previous 10 years By Age at Prevalence, Race/Ethnicity and Sex

_	Age Specific (Crude)										
Age at Prevalence	All Ages	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70-79	+08	All Ages
Race/Sex											
All Races ^c	0.0776%	0.0022%	0.0091%	0.0143%	0.0296%	0.0636%	0.1292%	0.2350%	0.3539%	0.3527%	0.0820%
Males	0.0824%	0.0031%	0.0125%	0.0173%	0.0346%	0.0766%	0.1497%	0.2650%	0.3971%	0.3955%	0.0941%
Females	0.0729%	0.0014%	0.0056%	0.0112%	0.0245%	0.0508%	0.1098%	0.2082%	0.3214%	0.3295%	0.0714%
White ^c Males Females	0.0861% 0.0907% 0.0814%	0.0025% 0.0033% 0.0016%	0.0095% 0.0129% 0.0059%	0.0145% 0.0175% 0.0112%	0.0312% 0.0364% 0.0256%	0.0663% 0.0799% 0.0525%	0.1378% 0.1586% 0.1176%	0.2568% 0.2884% 0.2279%	0.3805% 0.4247% 0.3466%	0.3697% 0.4133% 0.3464%	0.0874% 0.0999% 0.0762%
Black ^c Males Females	0.0448% 0.0501% 0.0401%	0.0012% 0.0018% -	0.0068% 0.0096% 0.0039%	0.0150% 0.0176% 0.0127%	0.0301% 0.0353% 0.0255%	0.0602% 0.0741% 0.0480%	0.1090% 0.1378% 0.0852%	0.1431% 0.1595% 0.1303%	0.1808% 0.2030% 0.1661%	0.1567% 0.1804% 0.1455%	0.0556% 0.0656% 0.0474%
Asian/Pacific Islander ^c Males Females	0.0496% 0.0520% 0.0474%	0.0016% 0.0022% -	0.0094% 0.0122% 0.0064%	0.0119% 0.0149% 0.0088%	0.0180% 0.0208% 0.0154%	0.0407% 0.0485% 0.0337%	0.0752% 0.0807% 0.0704%	0.1387% 0.1501% 0.1292%	0.2506% 0.2831% 0.2270%	0.2778% 0.3064% 0.2585%	0.0547% 0.0614% 0.0490%
Hispanic ^d Males Females	0.0346% 0.0356% 0.0334%	0.0022% 0.0030% 0.0013%	0.0079% 0.0111% 0.0044%	0.0089% 0.0115% 0.0059%	0.0210% 0.0253% 0.0162%	0.0470% 0.0543% 0.0394%	0.0906% 0.1011% 0.0808%	0.1679% 0.1714% 0.1650%	0.2701% 0.2982% 0.2500%	0.2568% 0.2279% 0.2730%	0.0602% 0.0649% 0.0553%

US 2003 cancer prevalence counts are based on 2003 cancer prevalence proportions from the SEER registries and 1/1/2003 US population estimates based on the average of 2002 and 2003 population estimates from the US Bureau of the Census. Prevalence was calculated using the First Malignant Primary Only for a person.

Statistics based on (b) SEER 9 Areas (c) SEER 11 Areas and Rural Georgia (d) NHIA for Hispanic for SEER 11 Areas and Rural Georgia excluding Hawaii and Seattle.

Maximum limited-duration prevalence: 28 years for 1975-2003 SEER 9 data; 13 years for 1990-2003 SEER 11 data (used to calculate prevalence for Hispanics and Asian Pacific Islanders).

g h

Percentages are age-adjusted to the 2000 US standard population by 5-year age groups.

(g) Cases diagnosed more than 28 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000). (h)Complete prevalence is obtained by summing 0 to <28 and >=28.

Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

bcd

Table XX-16 ORAL CAVITY AND PHARYNX CANCER (Invasive)

Estimated United States Cancer Prevalence Counts^a on January 1, 2003 By Race/Ethnicity, Sex and Years Since Diagnosis

Years Since Diagnosis	0 to <5	5 to <10	10 to <15	15 to <20	20 to <25	0 to <13 ^e	0 to <28 ^e	>=28 ^g	Complete ^h
Race/Sex									
All Races ^b	83,955	53,187	33,089	23,756	14,902	159,086	215,563	20,070	235,633
Males	55,821	34,234	20,500	14,600	8,756	104,017	138,069	11,982	150,051
Females	28,134	18,953	12,589	9,156	6,146	55,069	77,494	8,088	85,582
White ^b	72,358	46,686	29,436	21,420	13,273	138,642	189,210	17,097	206,307
Males	48,421	30,334	18,539	13,334	8,040	91,425	122,521	10,298	132,819
Females	23,937	16,352	10,897	8,086	5,233	47,217	66,689	6,799	73,488
Black ^b	7,329	3,836	2,187	1,486	991	12,543	16,171	951	17,122
Males	4,784	2,261	1,142	783	370	7,756	9,458	389	9,847
Females	2,545	1,575	1,045	703	621	4,787	6,713	562	7,275
Asian/Pacific Islander ^c	2,714	1,754	+	+	+	5,086	+	+	+
Males	1,702	1,078	+	+	+	3,161	+	+	+
Females	1,012	676	+	+	+	1,925	+	+	+
Hispanic ^d	3,409	1,978	+	+	+	6,159	+	+	+
Males	2,209	1,175	+	+	+	3,792	+	+	+
Females	1,200	803	+	+	+	2,367	+	+	+

Estimated prevalence percent^a on January 1, 2003, of the SEER 11 population diagnosed in the previous 10 years By Age at Prevalence, Race/Ethnicity and Sex

_	Age Specific (Crude)										
Age at Prevalence	All Ages	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70-79	80+	All Ages
Race/Sex											
All Races ^c	0.0428%	0.0003%	0.0016%	0.0049%	0.0116%	0.0369%	0.0920%	0.1476%	0.1783%	0.1545%	0.0450%
Males	0.0569%	0.0002%	0.0015%	0.0042%	0.0123%	0.0500%	0.1369%	0.2195%	0.2647%	0.2295%	0.0648%
Females	0.0290%	0.0004%	0.0017%	0.0056%	0.0109%	0.0239%	0.0495%	0.0835%	0.1132%	0.1137%	0.0284%
White ^c	0.0454%	0.0003%	0.0017%	0.0045%	0.0107%	0.0350%	0.0925%	0.1545%	0.1885%	0.1608%	0.0459%
Males	0.0604%	0.0002%	0.0014%	0.0036%	0.0118%	0.0481%	0.1380%	0.2290%	0.2765%	0.2431%	0.0663%
Females	0.0303%	0.0003%	0.0021%	0.0054%	0.0094%	0.0217%	0.0481%	0.0864%	0.1210%	0.1166%	0.0285%
Black ^c	0.0295%	_	0.0015%	0.0055%	0.0092%	0.0349%	0.0919%	0.1258%	0.1258%	0.0841%	0.0375%
Males	0.0397%	_	0.0025%	0.0057%	0.0086%	0.0433%	0.1475%	0.1933%	0.2014%	0.1158%	0.0554%
Females	0.0203%	_	_	0.0053%	0.0098%	0.0276%	0.0459%	0.0729%	0.0760%	0.0691%	0.0239%
Asian/Pacific Islander	0.0383%	_	0.0011%	0.0065%	0.0172%	0.0476%	0.0841%	0.1137%	0.1318%	0.1271%	0.0406%
Males	0.0493%	_	_	0.0066%	0.0162%	0.0655%	0.1138%	0.1695%	0.2006%	0.1701%	0.0561%
Females	0.0281%	-	-	0.0063%	0.0181%	0.0313%	0.0580%	0.0672%	0.0819%	0.0981%	0.0280%
Hispanic ^d	0.0137%	_	0.0013%	0.0020%	0.0059%	0.0182%	0.0442%	0.0799%	0.1166%	0.0905%	0.0250%
Males	0.0166%	_	0.0007%	0.0020%	0.0066%	0.0224%	0.0618%	0.1188%	0.1808%	0.0971%	0.0345%
Females	0.0106%	_	0.0019%	0.0020%	0.0052%	0.0139%	0.0280%	0.0478%	0.0708%	0.0868%	0.0173%

US 2003 cancer prevalence counts are based on 2003 cancer prevalence proportions from the SEER registries and 1/1/2003 US population estimates based on the average of 2002 and 2003 population estimates from the US Bureau of the Census. Prevalence was calculated using the First Malignant Primary Only for a person.

Statistics based on (b) SEER 9 Areas (c) SEER 11 Areas and Rural Georgia (d) NHIA for Hispanic for SEER 11 Areas and Rural Georgia excluding Hawaii and Seattle.

Maximum limited-duration prevalence: 28 years for 1975-2003 SEER 9 data; 13 years for 1990-2003 SEER 11 data (used to calculate prevalence for Hispanics and Asian Pacific Islanders).

Percentages are age-adjusted to the 2000 US standard population by 5-year age groups.

(g) Cases diagnosed more than 28 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000). (h)Complete prevalence is obtained by summing 0 to <28 and >=28.

Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

bcd

g h

Table XXI-12 OVARY CANCER (Invasive)

Estimated United States Cancer Prevalence Counts^a on January 1, 2003 By Race/Ethnicity and Years Since Diagnosis

Years Since Diagnosis	0 to <5	5 to <10	10 to <15	15 to <20	20 to <25	0 to <13 ^e	0 to <28 ^e	>=28 ^g	Complete
<u>Race</u> All Races ^b	54,837	28,750	22,267	19,029	13,944	97,850	145,849	25,991	171,840
White ^b	48,800	25,457	20,280	17,246	12,457	87,293	130,574	22,633	153,207
${\sf Black}^{\sf b}$	3,499	1,975	1,219	1,177	1,027	6,176	9,403	2,216	11,619
Asian/Pacific Islander ^c	1,793	910	+	+	+	3,101	+	+	+
Hispanic ^d	3,722	1,608	+	+	+	6,164	+	+	+

Estimated prevalence percent on January 1, 2003, of the SEER 11 population diagnosed in the previous 10 years By Age at Prevalence and Race/Ethnicity

	Age Specific (Crude)											
Age at Prevalence	All Ages	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70-79	80+	All Ages	
Race												
All Races ^c	0.0529%	0.0005%	0.0050%	0.0123%	0.0209%	0.0518%	0.1117%	0.1663%	0.1726%	0.1187%	0.0523%	
White ^c	0.0584%	0.0006%	0.0051%	0.0128%	0.0209%	0.0547%	0.1203%	0.1813%	0.1877%	0.1241%	0.0559%	
Black ^c	0.0273%	-	0.0034%	0.0085%	0.0160%	0.0343%	0.0604%	0.0894%	0.1040%	0.0993%	0.0321%	
Asian/Pacific Islande:	r ^c 0.0441%	-	0.0071%	0.0128%	0.0246%	0.0490%	0.0967%	0.1297%	0.1170%	0.0773%	0.0436%	
Hispanic ^d	0.0283%	0.0008%	0.0055%	0.0125%	0.0166%	0.0374%	0.0887%	0.1234%	0.1478%	0.1185%	0.0426%	

- Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

 US 2003 cancer prevalence counts are based on 2003 cancer prevalence proportions from the SEER registries and 1/1/2003 US population estimates based on the average of 2002 and 2003 population estimates from the US Bureau of the Census. Prevalence was calculated using the First Malignant Primary Only for a person.

 Statistics based on (b) SEER 9 Areas (c) SEER 11 Areas and Rural Georgia (d) NHIA for Hispanic for SEER 11 Areas and Rural Georgia excluding Hawaii and Seattle.

 Maximum limited-duration prevalence: 28 years for 1975-2003 SEER 9 data; 13 years for 1990-2003 SEER 11 data (used to calculate prevalence for Hispanics and Asian Pacific Islanders).

 Percentages are age-adjusted to the 2000 US standard population by 5-year age groups
- bcd

- Percentages are age-adjusted to the 2000 US standard population by 5-year age groups.

 (g) Cases diagnosed more than 28 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill g h
- et. al. 2000). (h)Complete prevalence is obtained by summing 0 to <28 and >=28. Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

Table XXII-16 PANCREAS CANCER (Invasive)

Estimated United States Cancer Prevalence Counts^a on January 1, 2003 By Race/Ethnicity, Sex and Years Since Diagnosis

Years Since Diagnosis	0 to <5	5 to <10	10 to <15	15 to <20	20 to <25	0 to <13 ^e	0 to <28 ^e	>=28 ^g	Complete ^h
Race/Sex									
All Races ^b	20,647	3,172	1,831	843	560	25,135	27,201	487	27,688
Males	10,136	1,450	855	344	216	12,214	13,101	201	13,302
Females	10,511	1,722	976	499	344	12,921	14,100	286	14,386
White ^b	17,505	2,575	1,469	583	475	21,195	22,724	396	23,120
Males	9,000	1,214	707	255	202	10,759	11,448	181	11,629
Females	8,505	1,361	762	328	273	10,436	11,276	215	11,491
Black ^b	2,297	381	270	210	78	2,808	3,265	210	3,475
Males	832	132	103	77	11	1,002	1,185	70	1,255
Females	1,465	249	167	133	67	1,806	2,080	140	2,220
Asian/Pacific Islander ^c	588	88	+	+	+	709	+	+	+
Males	238	38	+	+	+	287	+	+	+
Females	350	50	+	+	+	422	+	+	+
Hispanic ^d	1,040	243	+	+	+	1,382	+	+	+
Males	454	98	+	+	+	598	+	+	+
Females	586	145	+	+	+	784	+	+	+

Estimated prevalence percent^a on January 1, 2003, of the SEER 11 population diagnosed in the previous 10 years By Age at Prevalence, Race/Ethnicity and Sex

_	Age Specific (Crude)										
Age at Prevalence	All Ages	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70-79	+08	All Ages
Race/Sex											
All Races ^c	0.0074%	_	0.0002%	0.0003%	0.0013%	0.0047%	0.0128%	0.0264%	0.0407%	0.0341%	0.0079%
Males	0.0072%	-	-	0.0002%	0.0014%	0.0048%	0.0144%	0.0289%	0.0444%	0.0350%	0.0085%
Females	0.0075%	_	0.0003%	0.0004%	0.0012%	0.0046%	0.0113%	0.0241%	0.0379%	0.0337%	0.0073%
White ^c Males	0.0076% 0.0078%	- -	0.0002% -	0.0004% 0.0002%	0.0013% 0.0013%	0.0047% 0.0052%	0.0132% 0.0157%	0.0259% 0.0296%	0.0400% 0.0452%	0.0328% 0.0352%	0.0078% 0.0088%
Females	0.0074%	_	0.0002%	0.0006%	0.0013%	0.0042%	0.0107%	0.0226%	0.0361%	0.0315%	0.0069%
Black ^c Males Females	0.0068% 0.0051% 0.0082%	- - -	- - -	- - -	0.0018% 0.0029%	0.0059% 0.0054% 0.0062%	0.0140% 0.0123% 0.0155%	0.0356% 0.0300% 0.0400%	0.0448% 0.0359% 0.0507%	0.0387% - 0.0518%	0.0094% 0.0073% 0.0106%
Asian/Pacific Islander ^c Males Females	0.0063% 0.0053% 0.0071%	- - -	- - -	- - -	0.0007% - -	0.0035% 0.0018% 0.0051%	0.0094% 0.0069% 0.0116%	0.0229% 0.0248% 0.0213%	0.0389% 0.0396% 0.0384%	0.0420% 0.0471% 0.0386%	0.0071% 0.0068% 0.0074%
Hispanic ^d Males Females	0.0033% 0.0027% 0.0038%	- - -	- - -	- - -	0.0012% 0.0010% 0.0014%	0.0025% 0.0023% 0.0027%	0.0109% 0.0111% 0.0106%	0.0189% 0.0169% 0.0205%	0.0411% 0.0418% 0.0406%	0.0232% 0.0164% 0.0270%	0.0065% 0.0061% 0.0067%

US 2003 cancer prevalence counts are based on 2003 cancer prevalence proportions from the SEER registries and 1/1/2003 US population estimates based on the average of 2002 and 2003 population estimates from the US Bureau of the Census. Prevalence was calculated using the First Malignant Primary Only for a person.

Statistics based on (b) SEER 9 Areas (c) SEER 11 Areas and Rural Georgia (d) NHIA for Hispanic for SEER 11 Areas and Rural Georgia excluding Hawaii and Seattle.

Maximum limited-duration prevalence: 28 years for 1975-2003 SEER 9 data; 13 years for 1990-2003 SEER 11 data (used to calculate prevalence for Hispanics and Asian Pacific Islanders).

Percentages are age-adjusted to the 2000 US standard population by 5-year age groups.

(g) Cases diagnosed more than 28 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000). (h)Complete prevalence is obtained by summing 0 to <28 and >=28.

Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

bcd

g h

Table XXIII-12 PROSTATE CANCER (Invasive)

Estimated United States Cancer Prevalence Counts^a on January 1, 2003 By Race/Ethnicity and Years Since Diagnosis

Years Since Diagnosis	0 to <5	5 to <10	10 to <15	15 to <20	20 to <25	0 to <13 ^e	0 to <28 ^e	>=28 ^g	<u>Complete</u> h
<u>Race</u> All Races ^b	925,708	614,965	304,857	63,391	19,845	1,783,905	1,932,939	4,859	1,937,798
White ^b	773,341	523,009	274,055	57,530	18,039	1,514,464	1,649,702	5,179	1,654,881
Black ^b	118,253	73,974	24,993	5,010	1,583	212,481	224,210	424	224,634
Asian/Pacific Islander ^c	14,421	7,767	+	+	+	24,469	+	+	+
Hispanic ^d	41,897	24,137	+	+	+	72,885	+	+	+

Estimated prevalence percent on January 1, 2003, of the SEER 11 population diagnosed in the previous 10 years By Age at Prevalence and Race/Ethnicity

					Age S	pecific (C	rude)				Age-Adjustedf
Age at Prevalence	All Ages	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70-79	80+	All Ages
Race											
All Races ^c	0.9265%	-	_	0.0002%	0.0010%	0.0586%	0.8540%	4.1092%	8.7367%	8.0887%	1.1914%
White ^c	0.9647%	_	-	0.0003%	0.0008%	0.0517%	0.8272%	4.0939%	8.6806%	7.7780%	1.1720%
Black ^c	1.0228%	_	-	-	0.0023%	0.1489%	1.6709%	6.9826%	13.1509%	10.6339%	1.8581%
Asian/Pacific Islande	er ^c 0.4580%	-	-	-	-	0.0140%	0.2568%	1.5617%	4.9060%	6.0488%	0.6383%
Hispanic ^d	0.3175%	_	-	_	_	0.0286%	0.4839%	2.8681%	7.1871%	7.0898%	0.9377%

US 2003 cancer prevalence counts are based on 2003 cancer prevalence proportions from the SEER registries and 1/1/2003 US population estimates based on the average of 2002 and 2003 population estimates from the US Bureau of the Census. Prevalence was calculated using the First Malignant Primary Only for a person.

Statistics based on (b) SEER 9 Areas (c) SEER 11 Areas and Rural Georgia (d) NHIA for Hispanic for SEER 11 Areas and Rural Georgia excluding Hawaii and Seattle.

Maximum limited-duration prevalence: 28 years for 1975-2003 SEER 9 data; 13 years for 1990-2003 SEER 11 data (used to calculate prevalence for Hispanics and Asian Pacific Islanders).

bcd

g h

Percentages are age-adjusted to the 2000 US standard population by 5-year age groups.

(g) Cases diagnosed more than 28 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000). (h)Complete prevalence is obtained by summing 0 to <28 and >=28.

Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

⁺ Not available.

Table XXIV-16 STOMACH CANCER (Invasive)

Estimated United States Cancer Prevalence Counts^a on January 1, 2003 By Race/Ethnicity, Sex and Years Since Diagnosis

_									
Years Since Diagnosis	0 to <5	5 to <10	10 to <15	15 to <20	20 to <25	0 to <13 ^e	0 to <28 ^e	>=28 ^g	Complete ^h
Race/Sex									
All Races ^b	29,257	11,679	7,740	4,734	2,887	45,791	57,098	2,755	59,853
Males	17,694	6,632	3,862	2,471	1,570	26,701	32,717	1,582	34,299
Females	11,563	5,047	3,878	2,263	1,317	19,090	24,381	1,173	25,554
	•	•	•	•	·	, ·	•	•	
White ^b	22,152	8,813	5,772	3,642	2,409	34,543	43,412	2,233	45,645
Males	13,704	5,054	2,835	1,932	1,326	20,462	25,243	1,222	26,465
Females	8,448	3,759	2,937	1,710	1,083	14,081	18,169	1,011	19,180
	•	•	•		·	, ·	•	•	•
Black ^b	4,295	1,722	1,120	713	265	6,721	8,203	357	8,560
Males	2,291	918	624	349	162	3,606	4,391	206	4,597
Females	2,004	804	496	364	103	3,115	3,812	151	3,963
	•					, ·	•		.,
Asian/Pacific Islander ^c	2,403	1,080	+	+	+	3,937	+	+	+
Males	1,381	624	+	+	+	2,255	+	+	+
Females	1,022	456	+	+	+	1,682	+	+	+
Hispanic ^d	3,396	1,150	+		+	5,030			
	- ,	,	•	+	+	- ,	+	+	+
Males	1,918	561	+	+	+	2,709	+	+	+
Females	1,478	589	+	+	+	2,321	+	+	+

Estimated prevalence percent on January 1, 2003, of the SEER 11 population diagnosed in the previous 10 years By Age at Prevalence, Race/Ethnicity and Sex

_	Age Specific (Crude)										Age-Adjustedf
Age at Prevalence	All Ages	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70-79	+08	All Ages
Race/Sex											
All Races ^c	0.0159%	_	0.0001%	0.0005%	0.0026%	0.0086%	0.0214%	0.0498%	0.0949%	0.1118%	0.0172%
Males	0.0187%	_	_	0.0006%	0.0026%	0.0097%	0.0273%	0.0698%	0.1304%	0.1543%	0.0230%
Females	0.0131%	-	0.0002%	0.0003%	0.0025%	0.0075%	0.0158%	0.0320%	0.0682%	0.0887%	0.0127%
White ^c	0.0133%	-	0.0001%	0.0004%	0.0021%	0.0070%	0.0172%	0.0425%	0.0714%	0.0877%	0.0136%
Males	0.0159%	-	_	0.0005%	0.0022%	0.0078%	0.0221%	0.0610%	0.0997%	0.1236%	0.0185%
Females	0.0108%	-	0.0002%	0.0003%	0.0021%	0.0061%	0.0124%	0.0257%	0.0497%	0.0685%	0.0098%
Black ^c	0.0152%	_	_	0.0011%	0.0022%	0.0141%	0.0329%	0.0565%	0.1225%	0.1211%	0.0218%
Males	0.0166%	_	_	0.0016%	0.0024%	0.0171%	0.0375%	0.0786%	0.1659%	0.1195%	0.0271%
Females	0.0139%	_	_	_	0.0021%	0.0114%	0.0290%	0.0392%	0.0939%	0.1218%	0.0179%
Asian/Pacific Islander	0.0333%	_	_	_	0.0052%	0.0139%	0.0397%	0.0924%	0.2408%	0.3188%	0.0391%
Males	0.0394%	_	-	-	0.0051%	0.0154%	0.0549%	0.1232%	0.3283%	0.4112%	0.0519%
Females	0.0277%	_	_	_	0.0052%	0.0125%	0.0264%	0.0667%	0.1773%	0.2566%	0.0296%
Hispanic ^d	0.0115%	_	0.0004%	0.0005%	0.0037%	0.0120%	0.0300%	0.0629%	0.1248%	0.1756%	0.0239%
Males	0.0121%	_	_	0.0008%	0.0034%	0.0120%	0.0336%	0.0825%	0.1688%	0.2306%	0.0302%
Females	0.0109%	-	0.0007%	-	0.0041%	0.0121%	0.0267%	0.0468%	0.0935%	0.1448%	0.0194%

US 2003 cancer prevalence counts are based on 2003 cancer prevalence proportions from the SEER registries and 1/1/2003 US population estimates based on the average of 2002 and 2003 population estimates from the US Bureau of the Census. Prevalence was calculated using the First Malignant Primary Only for a person.

Statistics based on (b) SEER 9 Areas (c) SEER 11 Areas and Rural Georgia (d) NHIA for Hispanic for SEER 11 Areas and Rural Georgia excluding Hawaii and Seattle.

Maximum limited-duration prevalence: 28 years for 1975-2003 SEER 9 data; 13 years for 1990-2003 SEER 11 data (used to calculate prevalence for Hispanics and Asian Pacific Islanders).

Percentages are age-adjusted to the 2000 US standard population by 5-year age groups.

(g) Cases diagnosed more than 28 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000). (h)Complete prevalence is obtained by summing 0 to <28 and >=28.

Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

bcd

g h

Table XXV-12 TESTIS CANCER (Invasive)

Estimated United States Cancer Prevalence Counts^a on January 1, 2003 By Race/Ethnicity and Years Since Diagnosis

Years Since Diagnosis	0 to <5	5 to <10	10 to <15	15 to <20	20 to <25	0 to <13 ^e	0 to <28 ^e	>=28 ^g	Complete ^h
<u>Race</u> All Races ^b	38,559	33,206	30,241	24,435	18,120	90,268	151,951	19,479	171,430
White ^b	36,138	31,413	29,082	23,510	17,496	85,258	144,730	18,749	163,479
Black ^b	1,145	728	365	412	324	2,081	3,092	179	3,271
Asian/Pacific Islander ^c	611	466	+	+	+	1,333	+	+	+
Hispanic ^d	3,578	2,568	+	+	+	7,581	+	+	+

Estimated prevalence percent on January 1, 2003, of the SEER 11 population diagnosed in the previous 10 years By Age at Prevalence and Race/Ethnicity

					Age S	specific (C	rude)				Age-Adjustedf
Age at Prevalence	All Ages	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70-79	80+	All Ages
<u>Race</u>											
All Races ^c	0.0473%	0.0019%	0.0051%	0.0513%	0.1090%	0.0938%	0.0451%	0.0172%	0.0085%	0.0049%	0.0458%
White ^c	0.0570%	0.0019%	0.0059%	0.0627%	0.1329%	0.1115%	0.0530%	0.0204%	0.0103%	0.0057%	0.0550%
Black ^c	0.0109%	_	0.0028%	0.0080%	0.0265%	0.0239%	0.0128%	-	-	-	0.0109%
Asian/Pacific Islande	er ^c 0.0167%	0.0029%	0.0022%	0.0184%	0.0321%	0.0353%	0.0161%	0.0035%	-	-	0.0157%
Hispanic ^d	0.0309%	0.0023%	0.0053%	0.0426%	0.0698%	0.0552%	0.0215%	0.0112%	_	-	0.0291%

US 2003 cancer prevalence counts are based on 2003 cancer prevalence proportions from the SEER registries and 1/1/2003 US population estimates based on the average of 2002 and 2003 population estimates from the US Bureau of the Census. Prevalence was calculated using the First Malignant Primary Only for a person.

Statistics based on (b) SEER 9 Areas (c) SEER 11 Areas and Rural Georgia (d) NHIA for Hispanic for SEER 11 Areas and Rural Georgia excluding Hawaii and Seattle.

Maximum limited-duration prevalence: 28 years for 1975-2003 SEER 9 data; 13 years for 1990-2003 SEER 11 data (used to calculate prevalence for Hispanics and Asian Pacific Islanders).

bcd

g h

Percentages are age-adjusted to the 2000 US standard population by 5-year age groups.

(g) Cases diagnosed more than 28 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000). (h)Complete prevalence is obtained by summing 0 to <28 and >=28.

Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

⁺ Not available.

Table XXVI-16 THYROID CANCER (Invasive)

Estimated United States Cancer Prevalence Counts^a on January 1, 2003 By Race/Ethnicity, Sex and Years Since Diagnosis

Years Since Diagnosis	0 to <5	5 to <10	10 to <15	15 to <20	20 to <25	0 to <13 ^e	0 to <28 ^e	>=28 ^g	Complete ^h
Race/Sex									
All Races ^b	96,001	67,200	49,620	39,165	30,810	195,091	300,771	46,653	347,424
Males	22,362	15,147	11,247	8,504	6,715	44,975	68,236	11,039	79,275
Females	73,639	52,053	38,373	30,661	24,095	150,116	232,535	35,614	268,149
White ^b	83,827	59,397	44,417	35,115	27,840	171,682	266,801	42,152	308,953
Males	20,222	13,714	10,277	7,693	6,146	40,719	62,010	9,360	71,370
Females	63,605	45,683	34,140	27,422	21,694	130,963	204,791	32,792	237,583
Black ^b	5,754	3,734	2,454	1,844	1,482	11,207	16,174	1,933	18,107
Males	985	678	550	362	226	2,065	2,906	210	3,116
Females	4,769	3,056	1,904	1,482	1,256	9,142	13,268	1,723	14,991
Asian/Pacific Islander ^c	4,246	2,776	+	+	+	8,268	+	+	+
Males	842	474	+	+	+	1,525	+	+	+
Females	3,404	2,302	+	+	+	6,743	+	+	+
Hispanic ^d	8,033	5,313	+	+	+	15,683	+	+	+
Males	1,521	957	+	+	+	2,913	+	+	+
Females	6,512	4,356	+	+	+	12,770	+	+	+

Estimated prevalence percent^a on January 1, 2003, of the SEER 11 population diagnosed in the previous 10 years By Age at Prevalence, Race/Ethnicity and Sex

_					Age S	pecific (C	rude)				Age-Adjustedf
Age at Prevalence	All Ages	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70-79	+08	All Ages
Race/Sex											
All Races ^c	0.0542%	_	0.0036%	0.0288%	0.0682%	0.0936%	0.1008%	0.0995%	0.0836%	0.0581%	0.0544%
Males	0.0246%	-	0.0013%	0.0079%	0.0247%	0.0367%	0.0526%	0.0633%	0.0579%	0.0429%	0.0259%
Females	0.0830%	_	0.0060%	0.0508%	0.1129%	0.1499%	0.1466%	0.1317%	0.1030%	0.0664%	0.0820%
White ^c Males Females	0.0579% 0.0271% 0.0886%	- -	0.0040% 0.0015% 0.0067%	0.0320% 0.0088% 0.0570%	0.0743% 0.0270% 0.1249%	0.1010% 0.0404% 0.1629%	0.1044% 0.0567% 0.1510%	0.1009% 0.0660% 0.1329%	0.0828% 0.0595% 0.1007%	0.0568% 0.0440% 0.0636%	0.0574% 0.0278% 0.0872%
Black ^c Males Females	0.0244% 0.0094% 0.0380%	- - -	0.0014% - 0.0018%	0.0087% - 0.0157%	0.0306% 0.0110% 0.0479%	0.0408% 0.0127% 0.0654%	0.0562% 0.0240% 0.0830%	0.0666% 0.0328% 0.0932%	0.0594% 0.0461% 0.0682%	0.0391% 0.0187% 0.0489%	0.0283% 0.0124% 0.0414%
Asian/Pacific Islander ^c Males Females	0.0568% 0.0223% 0.0891%	- - -	0.0034% - 0.0067%	0.0286% 0.0087% 0.0483%	0.0635% 0.0207% 0.1040%	0.0907% 0.0330% 0.1427%	0.1088% 0.0444% 0.1651%	0.1101% 0.0652% 0.1475%	0.1005% 0.0527% 0.1351%	0.0825% 0.0464% 0.1068%	0.0565% 0.0238% 0.0855%
Hispanic ^d Males Females	0.0348% 0.0124% 0.0584%	- - -	0.0028% 0.0007% 0.0050%	0.0211% 0.0056% 0.0395%	0.0464% 0.0127% 0.0847%	0.0760% 0.0251% 0.1283%	0.0935% 0.0385% 0.1442%	0.0973% 0.0586% 0.1292%	0.0819% 0.0459% 0.1076%	0.0784% 0.0517% 0.0934%	0.0470% 0.0197% 0.0736%

US 2003 cancer prevalence counts are based on 2003 cancer prevalence proportions from the SEER registries and 1/1/2003 US population estimates based on the average of 2002 and 2003 population estimates from the US Bureau of the Census. Prevalence was calculated using the First Malignant Primary Only for a person.

Statistics based on (b) SEER 9 Areas (c) SEER 11 Areas and Rural Georgia (d) NHIA for Hispanic for SEER 11 Areas and Rural Georgia excluding Hawaii and Seattle.

Maximum limited-duration prevalence: 28 years for 1975-2003 SEER 9 data; 13 years for 1990-2003 SEER 11 data (used to calculate prevalence for Hispanics and Asian Pacific Islanders).

g h

Percentages are age-adjusted to the 2000 US standard population by 5-year age groups.

(g) Cases diagnosed more than 28 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000). (h)Complete prevalence is obtained by summing 0 to <28 and >=28.

Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

bcd

Table XXVII-16 URINARY BLADDER CANCER (Invasive)

Estimated United States Cancer Prevalence Counts^a on January 1, 2003 By Race/Ethnicity, Sex and Years Since Diagnosis

Years Since Diagnosis	0 to <5	5 to <10	10 to <15	15 to <20	20 to <25	0 to <13 ^e	0 to <28 ^e	>=28 ^g	Complete ^h
Race/Sex									
All Races ^b	184,975	124,284	80,177	50,903	29,858	361,817	480,880	24,885	505,765
Males	138,238	92,488	59,440	37,669	20,884	269,757	356,081	16,232	372,313
Females	46,737	31,796	20,737	13,234	8,974	92,060	124,799	8,653	133,452
White ^b	172,663	117,170	76,414	48,335	28,633	339,580	453,270	19,661	472,931
Males	129,801	87,297	56,633	35,785	20,035	254,025	336,538	12,587	349,125
Females	42,862	29,873	19,781	12,550	8,598	85,555	116,732	7,074	123,806
Black ^b	7,532	4,159	2,470	1,651	751	13,538	16,891	398	17,289
Males	4,704	2,922	1,791	1,217	500	8,976	11,348	317	11,665
Females	2,828	1,237	679	434	251	4,562	5,543	81	5,624
Asian/Pacific Islander ^c	2,252	1,389	+	+	+	4,175	+	+	+
Males	1,717	1,032	+	+	+	3,147	+	+	+
Females	535	357	+	+	+	1,028	+	+	+
Hispanic ^d	5,161	3,100	+	+	+	9,573	+	+	+
Males	3,864	2,337	+	+	+	7,155	+	+	+
Females	1,297	763	+	+	+	2,418	+	+	+

Estimated prevalence percent^a on January 1, 2003, of the SEER 11 population diagnosed in the previous 10 years By Age at Prevalence, Race/Ethnicity and Sex

_					Age S	pecific (C	rude)				Age-Adjustedf
Age at Prevalence	All Ages	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70-79	+08	All Ages
Race/Sex											
All Races ^c	0.0895%	0.0001%	0.0002%	0.0016%	0.0062%	0.0253%	0.0982%	0.3007%	0.6083%	0.7164%	0.0978%
Males	0.1360%	0.0002%	0.0002%	0.0021%	0.0082%	0.0389%	0.1558%	0.4977%	1.0834%	1.4232%	0.1731%
Females	0.0440%	-	_	0.0011%	0.0041%	0.0119%	0.0435%	0.1249%	0.2506%	0.3323%	0.0424%
White ^c	0.1067%	0.0001%	0.0001%	0.0020%	0.0071%	0.0286%	0.1126%	0.3483%	0.6866%	0.7747%	0.1101%
Males	0.1613%	_	_	0.0026%	0.0091%	0.0432%	0.1755%	0.5702%	1.2179%	1.5610%	0.1939%
Females	0.0524%	-	_	0.0013%	0.0051%	0.0138%	0.0512%	0.1453%	0.2793%	0.3535%	0.0475%
Black ^c	0.0303%	_	_	0.0008%	0.0034%	0.0147%	0.0575%	0.1323%	0.2543%	0.3347%	0.0454%
Males	0.0432%	_	_	_	0.0058%	0.0252%	0.0984%	0.2093%	0.4230%	0.5678%	0.0757%
Females	0.0186%	_	-	_	0.0013%	0.0055%	0.0236%	0.0719%	0.1434%	0.2238%	0.0251%
Asian/Pacific Islander	0.0357%	_	_	_	0.0025%	0.0101%	0.0315%	0.1011%	0.2665%	0.4219%	0.0428%
Males	0.0553%	_	_	_	0.0040%	0.0165%	0.0529%	0.1783%	0.4621%	0.7563%	0.0751%
Females	0.0173%	_	_	_	_	0.0042%	0.0127%	0.0368%	0.1248%	0.1964%	0.0188%
Hispanic ^d	0.0208%	_	_	0.0009%	0.0033%	0.0110%	0.0430%	0.1333%	0.2852%	0.3809%	0.0469%
Males	0.0302%	_	_	0.0010%	0.0030%	0.0163%	0.0668%	0.2339%	0.5195%	0.7357%	0.0843%
Females	0.0110%	_	-	0.0008%	0.0036%	0.0056%	0.0210%	0.0503%	0.1180%	0.1814%	0.0207%

US 2003 cancer prevalence counts are based on 2003 cancer prevalence proportions from the SEER registries and 1/1/2003 US population estimates based on the average of 2002 and 2003 population estimates from the US Bureau of the Census. Prevalence was calculated using the First Malignant Primary Only for a person.

Statistics based on (b) SEER 9 Areas (c) SEER 11 Areas and Rural Georgia (d) NHIA for Hispanic for SEER 11 Areas and Rural Georgia excluding Hawaii and Seattle.

Maximum limited-duration prevalence: 28 years for 1975-2003 SEER 9 data; 13 years for 1990-2003 SEER 11 data (used to calculate prevalence for Hispanics and Asian Pacific Islanders).

g h

Percentages are age-adjusted to the 2000 US standard population by 5-year age groups.

(g) Cases diagnosed more than 28 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000). (h)Complete prevalence is obtained by summing 0 to <28 and >=28.

Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

bcd

Table XXVIII-12 CHILDHOOD CANCER (Invasive, <20 Years old at diagnosis)

Estimated United States Cancer Prevalence Counts^a on January 1, 2003 By Race/Ethnicity, Sex and Years Since Diagnosis

Years Since Diagnosis	0 to <5	5 to <10	10 to <15	15 to <20	20 to <25	0 to <13 ^e	0 to <28 ^e	>=28 ^f	Complete
Race/Sex									
All Races ^b	57,723	47,688	41,411	35,310	30,062	131,069	227,872	+	+
Males	30,378	25,199	21,883	17,935	14,601	69,413	117,016	+	+
Females	27,345	22,489	19,528	17,375	15,461	61,656	110,856	+	+
White ^b	48,687	39,754	35,270	30,871	26,365	110,249	194,768	+	+
Males	25,649	21,010	18,833	15,739	12,931	58,570	100,428	+	+
Females	23,038	18,744	16,437	15,132	13,434	51,679	94,340	+	+
Black ^b	5,798	5,098	4,107	2,953	2,619	13,408	21,893	+	+
Males	2,965	2,611	2,046	1,435	1,146	6,854	10,748	+	+
Females	2,833	2,487	2,061	1,518	1,473	6,554	11,145	+	+
Asian/Pacific Islander ^c	1,897	1,548	+	+	+	4,254	+	+	+
Males	1,028	836	+	+	+	2,258	+	+	+
Females	869	712	+	+	+	1,996	+	+	+
Hispanic ^d	8,930	6,276	+	+	+	18,521	+	+	+
Males	4,780	3,388	+	+	+	10,057	+	+	+
Females	4,150	2,888	+	+	+	8,464	+	+	+

US 2003 cancer prevalence counts are based on 2003 cancer prevalence proportions from the SEER registries and 1/1/2003 US population estimates based on the average of 2002 and 2003 population estimates from the US Bureau of the Census. Prevalence was calculated using the First Malignant Primary Only for a person.

Statistics based on (b) SEER 9 Areas (c) SEER 11 Areas and Rural Georgia (d) NHIA for Hispanic for SEER 11 Areas and Rural Georgia excluding Hawaii and Seattle.

Maximum limited-duration prevalence: 28 years for 1975-2003 SEER 9 data; 13 years for 1990-2003 SEER 11 data (used to calculate prevalence for Hispanics and Asian Pacific Islanders).

(f) Cases diagnosed more than 28 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000). (g)Complete prevalence is obtained by summing 0 to <28 and >=28.

Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

Not available.

bcd

f g

⁺ Not available.